

## CADTH HEALTH TECHNOLOGY ASSESSMENT

# Comparative Value of Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP) Testing in Combination Versus Individually for the Diagnosis of Undifferentiated Patients With Suspected Inflammatory Disease or Serious Infection: A Systematic Review and Economic Analysis

Product Line: Health Technology Assessment  
Issue Number: 140  
Publication Date: November 2015  
Report Length: 65 Pages

**Authors:** Nazila Assasi<sup>2,3</sup>, Gord Blackhouse<sup>2,3</sup>, Kaitryn Campbell<sup>2,3</sup>, Robert B Hopkins<sup>2,3</sup>, Mitchell Levine<sup>1,2,3</sup>, Trevor Richter<sup>4</sup>, Anthony Budden<sup>4</sup>

**Cite as:** Comparative value of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) testing in combination versus individually for the diagnosis of undifferentiated patients with suspected inflammatory disease or serious infection: a systematic review and economic analysis. Ottawa: CADTH; 2015 Nov. (CADTH health technology assessment; no.140).

Production of this report is made possible by financial contributions from Health Canada and the governments of Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Northwest Territories, Nova Scotia, Nunavut, Prince Edward Island, Saskatchewan, and Yukon. The Canadian Agency for Drugs and Technologies in Health (CADTH) takes sole responsibility for the final form and content of this report. The views expressed herein do not necessarily represent the views of Health Canada or any provincial or territorial government.

Copyright © CADTH 2015. You are permitted to reproduce this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH.

**About CADTH:** CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

**Funding:** CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

**Views:** The views expressed herein are those of CADTH and do not necessarily reflect the views of our funders.

Contact [requests@cadth.ca](mailto:requests@cadth.ca) with inquiries about this notice or legal matters relating to CADTH services.

ISSN: 2369-7377

---

<sup>1</sup> Centre for Evaluation of Medicine, St. Joseph's Healthcare Hamilton, Hamilton, Ontario.

<sup>2</sup> Programs for the Assessment of Technology in Health (PATH) Research Institute, St. Joseph's Healthcare Hamilton, Hamilton, Ontario.

<sup>3</sup> Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, Ontario.

<sup>4</sup> Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, Ontario.

## Reviewers

### External Reviewers

This document was externally reviewed by content experts and the following individuals granted permission to be cited.

Dr. Nader Khalidi  
MD, FRCPC  
Associate Professor  
St. Joseph's Healthcare Hamilton  
McMaster University  
Hamilton, Ontario

David B. Robinson  
MD, MSc, FRCPC  
Head, Section of Rheumatology, Associate  
Professor of Medicine  
University of Manitoba  
Winnipeg, Manitoba

### Authorship

Nazila Assasi contributed to the development of the study protocol, screening of literature, data extraction, and analysis. She was responsible for conducting the clinical review and the write-ups. She reviewed the final report and addressed the reviewers' comments.

Gord Blackhouse conducted the economic review and primary economic analysis in the report. He was responsible for the write-up of the economic review and the primary economic section of the report. He also reviewed and provided feedback for all sections of the report.

Kaitryn Campbell designed and executed search strategies and wrote the literature search methods and appendix.

Robert Hopkins conducted the research design, statistical analysis, interpretation of results, and writing and reviewing of the report.

Mitchell Levine reviewed the analysis and provided input for revisions and discussion.

Trevor Richter conceptualized the study design and conduct, contributed to the interpretation of data, drafted portions of the draft report, and reviewed and helped to develop the final report.

Anthony Budden reviewed and revised the manuscript.

### Acknowledgements

The authors would like to acknowledge Rhonda Boudreau for her contributions to the report.

### Conflicts of Interest

Gordon Blackhouse has received funding for conducting educational workshops.

No other conflicts of interest were reported.

# Table of Contents

1.	INTRODUCTION .....	1
1.1	Context and Policy Issues .....	1
1.2	Background Information.....	1
2.	RESEARCH QUESTIONS .....	2
3.	METHODS.....	2
3.1	Literature Search Strategy.....	2
3.2	Selection Criteria and Methods.....	2
3.3	Exclusion Criteria.....	3
3.4	Critical Appraisal of Individual Studies .....	3
3.4.1	Clinical review .....	3
3.4.2	Economic review .....	4
3.5	Data Analyses and Synthesis .....	4
3.5.1	Clinical review .....	4
3.5.2	Economic review .....	6
4.	SUMMARY OF CLINICAL EVIDENCE.....	7
4.1	Quantity of Research Available.....	7
4.2	Summary of Study Characteristics.....	7
4.3	Summary of Critical Appraisal.....	8
4.3.1	Risk of bias.....	8
4.3.2	Applicability .....	8
4.4	Summary of Findings.....	9
4.4.1	Diagnostic performance of ESR and CRP, when performed individually and in combination, for diagnosis of different conditions .....	9
4.4.2	Comparative diagnostic performance of ESR and CRP, when performed individually and in combination for different conditions.....	12
5.	SUMMARY OF ECONOMIC EVIDENCE .....	15
5.1	Quantity of Research Available.....	15
5.2	Summary of Critical Appraisal.....	15
5.3	Summary of Findings.....	15
6.	PRIMARY ECONOMIC EVALUATION.....	16
6.1	Methods.....	16
6.1.1	Type of evaluation .....	16
6.1.2	Target population.....	16
6.1.3	Comparators.....	16
6.1.4	Perspective.....	16
6.1.5	Model structure.....	16
6.1.6	Clinical model inputs.....	17
6.1.7	Resource use and costs .....	19
6.1.8	Sensitivity analysis .....	20
6.2	Results .....	20
6.2.1	Base-case results.....	20
6.2.2	Sensitivity analysis .....	23

7. DISCUSSION .....	28
7.1 Summary of Main Findings .....	28
7.2 Strengths and Limitations .....	29
7.3 Generalizability of Findings.....	30
7.4 Other Considerations.....	30
REFERENCES .....	31
Appendix 1: Literature Search Strategy.....	34
Appendix 2: Title and Abstract Screening Checklist .....	36
Appendix 3: Full Text Screening Checklist .....	37
Appendix 4: QUADAS-2 Tool for the Quality Assessment of Diagnostic Accuracy Studies <sup>13</sup> .....	38
Appendix 5: Clinical Data Abstraction Form .....	41
Appendix 6: Details of Outcome Measures for Assessment of Diagnostic Test Performance ...	43
Appendix 7: Selection of Included Studies .....	46
Appendix 8: List of Included and Excluded Studies .....	47
Appendix 9: Characteristics of Included Studies.....	50
Appendix 10: Risk of Bias and Applicability in the Included Diagnosis Studies (Results of QUADAS-2 Quality Assessment) <sup>13</sup> .....	53
Appendix 11: Test Characteristics and Estimated Test Results Using Data From Included Studies.....	56
Appendix 12: Diagnostic Performance of ESR and CRP Individually and in Combination Compared With the Reference Standard.....	58

# 1. Introduction

## 1.1 Context and Policy Issues

Patients who have suspected inflammatory disease or serious infection may undergo a diagnostic workup that involves multiple laboratory tests. Two such laboratory tests are erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), non-specific blood tests often ordered together that are well established and widely used to aid the diagnosis of numerous conditions. The simultaneous and widespread use of both tests has raised concerns about their potential overuse, particularly if they provide little valuable information regarding patient management and outcomes.

The aim of this report is to address the issue of when, if ever, it is appropriate to concurrently test ESR and CRP (as opposed to testing only ESR or CRP) to help diagnose inflammatory disease or serious infection. Accordingly, research questions (see section 2) were developed to explore the added value associated with performing both tests rather than one.

## 1.2 Background Information

CRP and ESR are among the most widely used diagnostic tests in detecting inflammatory conditions that may be caused by infection, autoimmune disorders, malignancies, or tissue necrosis.<sup>1</sup> The CRP test measures the level of a plasma protein (C-reactive protein) produced by liver cells in response to acute inflammation or infection. Unlike CRP, which is a direct measure of inflammatory response, ESR is an indirect measure of the level of inflammation in the body. ESR measures the rate at which red blood cells settle in a specially designated tube of anticoagulated blood, an effect that is altered by proteins associated with an inflammatory response.

Both CRP and ESR are usually increased in acute inflammatory conditions. However, patterns of response are different for each test. CRP rises within hours of onset of an infection or inflammatory condition and returns to normal within three to seven days if the acute process is resolved. ESR, on the other hand, increases in a slower manner and remains elevated for a longer period of time.<sup>2</sup> In addition, ESR is a non-specific measure that can be affected by factors other than inflammation, such as the size, shape, and number of red blood cells; levels of serum fibrinogen and immunoglobulins; renal function; age and sex; pregnancy; and use of medications.<sup>2,3</sup> Because of these differences, CRP testing is often chosen over ESR in the assessment of early inflammation;<sup>2,4-6</sup> however, there is no consensus on which single test is preferred<sup>3,7</sup> and as a result, physicians often request both tests. Based on statistics provided by Alberta Health Services, of the 650,000 requests for ESR and CRP tests in the province of Alberta in 2013, 45% were for both tests.<sup>8</sup>

There is scarce data to support the simultaneous use of CRP and ESR. In addition, it has been shown that, when conducted simultaneously, CRP and ESR are likely to yield concordant results 67% to 81% of the time.<sup>9-11</sup> Data from a recent study in an academic tertiary care children's hospital in the US suggested that elimination of concurrent CRP and ESR testing in both pediatric and adult practice could result in cost savings for that hospital of approximately \$250,000 to \$400,000 per year.<sup>10</sup>

## 2. Research Questions

1. What is the comparative diagnostic performance of ESR + CRP (i.e., combined) versus ESR or CRP (i.e., either test alone), quantified as sensitivity, specificity, positive and negative predictive values, and overall accuracy, for different conditions?
2. What is the comparative cost-effectiveness for ESR + CRP versus ESR or CRP (differential cost versus differential outcome) for different conditions?

## 3. Methods

### 3.1 Literature Search Strategy

The literature search was performed by an information specialist using a peer-reviewed search strategy.

Published literature was identified by searching the following bibliographic databases: PubMed, and The Cochrane Library (2014, Issue 6) via Wiley. The search strategy comprised both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concepts were erythrocyte sedimentation rate and C-reactive protein.

No methodological filters were applied. Where possible, retrieval was limited to the human population, items published between January 2004 and June 11, 2014, and the English language. Editorials, comments, letters, and newspaper articles were excluded from the search results. See Appendix 1 for the detailed search strategy.

The initial search was completed on June 11, 2014. Regular alerts were established to update the search until the publication of the final report. Regular search updates were performed on databases that do not provide alert services.

To complement the initial search, a second search of the same databases was performed on January 15, 2015. Retrieval was limited to items published between January 1980 and January 15, 2015 and the English language.

Grey literature (literature that is not commercially published) was identified by searching the CADTH Grey Matters checklist (<http://www.cadth.ca/resources/grey-matters>), which includes the websites of regulatory agencies, health technology assessment agencies, clinical guideline repositories, and professional associations. Google and other Internet search engines were used to search for additional Web-based materials. These searches were supplemented by reviewing the bibliographies of key papers and through contacts with appropriate experts and industry. See Appendix 1 for more information on the grey literature search strategy.

### 3.2 Selection Criteria and Methods

Studies suitable for inclusion were selected from those identified through the literature search, using the criteria listed in Table 1.

**Table 1: Inclusion Criteria**

<b>Population</b>	Any undifferentiated population not being tested to monitor an existing condition
<b>Intervention</b>	ESR and CRP used in combination
<b>Comparators</b>	ESR or CRP alone
<b>Outcomes</b>	<p>Diagnostic test performance:</p> <ul style="list-style-type: none"> <li>• Sensitivity</li> <li>• Specificity</li> <li>• Positive likelihood ratio</li> <li>• Negative likelihood ratio</li> <li>• Area under the receiver operating characteristic (ROC) curve (AUC)</li> <li>• Positive predictive value</li> <li>• Negative predictive value</li> <li>• Rates of false-positive tests</li> <li>• Rates of false-negative tests</li> <li>• Overall diagnostic accuracy</li> </ul> <p>Cost per outcome unit Cost per QALY ICER</p>
<b>Study types</b>	RCTs, prospective or retrospective observational (non-randomized) studies (cross-sectional diagnostic studies, cohort, case-control), economic evaluations

ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year; RCT = randomized controlled trial.

Two reviewers independently screened the titles and abstracts for relevance using a predefined checklist (Appendix 2). Any discrepancies between reviewers were resolved by consensus. Full texts of relevant titles and abstracts were retrieved, and assessed by two independent reviewers to make inclusion and exclusion decisions, using explicit predetermined criteria (Appendix 3). Discrepancies between the reviewers were resolved by consensus, consulting a third reviewer when necessary.

### 3.3 Exclusion Criteria

Studies were excluded if they: did not include a defined population/condition; included tests that use the Wintrobe method for ESR; performed tests outside a central laboratory (e.g., in a physician’s office); or utilized point-of-care methodology for performing the tests of interest. The Westerglen method is found to be the preferred method to measure ESR compared with the Wintrobe method.<sup>12</sup>

## 3.4 Critical Appraisal of Individual Studies

### 3.4.1 Clinical review

The methodological quality of the included diagnostic studies was assessed using the Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2; Appendix 4).<sup>13</sup> The QUADAS-2 is a tool that evaluates the risk of bias in a study’s selection of patients, index test, reference standard, and flow and timing. The tool also addresses concerns about the applicability of tests and provides signalling questions to help identify potential biases.

Data from all included studies were extracted into predefined data abstraction forms (Appendix 5). Relevant data were directly extracted from the text or tables by two independent reviewers. The data extraction forms were piloted by the reviewers, a priori, and a calibration exercise using data from 25% of studies was undertaken to ensure consistency between the reviewers. Any disagreements in data extraction were discussed and resolved by consensus.

### 3.4.2 Economic review

The Drummond checklist was used to assess the methodologic quality of economic reviews.

## 3.5 Data Analyses and Synthesis

### 3.5.1 Clinical review

#### Outcomes

Statistical outcomes that assessed differences in diagnostic test performance included sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, area under the curve (AUC), positive predictive value, and negative predictive value. A definition of each outcome measure is provided in Table 3. More details on how each of these methods was derived are provided in Appendix 6.

**Table 2: Two-by-Two Contingency Table Comparing an Index Test With a Reference Standard**

Index Test	Reference Test	
	Positive	Negative
Positive	TP	FP
Negative	FN	TN

FN = false-negative, when the negative index test disagrees with the positive reference standard; FP = false-positive, when the positive index test disagrees with the negative reference standard; TN = true-negative, when the negative index test agrees with the negative reference standard; TP = true-positive, when the positive index test agrees with the positive reference standard.

**Table 3: Definitions of Diagnostic Accuracy Measures**

Measure	Definition	Formula
<b>Sensitivity</b>	The proportion of persons with the disease who are correctly identified by a test	$TP/(TP+FN)$
<b>Specificity</b>	The proportion of persons without a disease who are correctly identified by a test	$TN/(TN+FP)$
<b>Positive Predictive Value</b>	The proportion of patients with positive test results who are correctly diagnosed	$TP/(TP+FP)$
<b>Negative Predictive Value</b>	The proportion of patients with negative test results who are correctly diagnosed	$TN/(TN+FN)$
<b>Positive Likelihood Ratio</b>	A ratio that indicates how much more likely it is to get a positive test result in the diseased group versus the non-diseased group	$\text{sensitivity}/(1-\text{specificity})$
<b>Negative Likelihood Ratio</b>	A ratio that indicates how much more likely it is to get a negative test in the non-diseased group versus the diseased group	$(1-\text{sensitivity})/\text{specificity}$
<b>AUC</b>	The probability that a randomly chosen diseased patient is correctly diagnosed with greater suspicion than a randomly chosen non-diseased patient	A plot of the sensitivity versus $1 - \text{specificity}$ , where different points on the curve correspond to different test thresholds
<b>Overall Diagnostic Accuracy</b>	Proportion of correctly classified patients among all patients	$(TP+TN)/(TP+FP+TN+FN)$

AUC = area under the receiver operating characteristic (ROC) curve; FN = false-negative, when the negative index test disagrees with the positive reference standard; FP = false-positive, when the positive index test disagrees with the negative reference standard; TN = true-negative, when the negative index test agrees with the negative reference standard; TP = true-positive, when the positive index test agrees with the positive reference standard.

This report uses measures of sensitivity, specificity, and the global measure of overall diagnostic accuracy to report differences in diagnostic performance of combined ESR and CRP testing versus either of the tests alone.

## Comparisons

Each of the diagnostic performance measures was estimated for the comparison between ESR, CRP, and a combination of these two tests. Since different definitions are used in the literature for the combination of ESR and CRP tests (e.g., concurrent, sequential, etc.), combined testing has been defined in this review as the simultaneous administration of ESR and CRP.

In this review, combined testing was divided into two categories:

- ESR + CRP — defined as a combined test where the reported study findings for both ESR and CRP tests were positive
- ESR/CRP — defined as a combined test where the study findings for either ESR or CRP were positive.

## Direct and indirect comparisons

The analysis of the diagnostic test performance involves two steps. In the first step, the direct comparison between each of the four comparators — ESR + CRP versus reference standard, ESR/CRP versus reference standard, ESR alone versus reference standard, and CRP alone versus reference standard — was estimated for each study. When there was more than one study with the same disease condition, the results of multiple studies of the same test for a particular condition (e.g., ESR for the diagnosis of periprosthetic infection) were pooled to create one pooled estimate. A random effects meta-analysis was not possible, since this method requires more than four different studies reporting the same outcome to provide sufficiently diverse data for a statistical convergence in STATA. Since no more than four similar studies (in terms of tests, conditions, and outcomes) were identified by the review, a fixed effects analysis was used, with a simple sum of the elements in the two-by-two tables.<sup>14</sup>

To determine the relative performance of combined ESR and CRP testing (i.e., ESR + CRP or ESR/CRP) versus individual ESR or CRP testing, indirect comparisons were conducted to provide a comparative estimate between the two tests. The indirect comparison was estimated with the publicly available indirect treatment comparison software (<https://www.cadth.ca/resources/itc-user-guide>) developed for CADTH by Wells et al. (2009)<sup>15</sup> and based on the Bucher method of indirect comparisons.<sup>16</sup> The Bucher method allows indirect comparisons between relative test performances if the patient populations are similar. Therefore, this review conducted an indirect comparison across studies with the same disease condition. All of the included studies used all study tests (i.e., ESR and CRP individually and in combination) on a common set of patients, and the results were dependent on patients selected.

By conducting pairwise estimates, this review obtained results that reflect relative values for sensitivity, specificity, etc. Because the relative values are ratios of values from each test, the results can be greater than 1.0 (e.g., if the first test had 90% sensitivity and the second test had 80% sensitivity, then the relative sensitivity is  $0.90/0.80 = 1.125$ ). Thus the range for these relative results can exceed the usual upper limit of 1.0 of diagnostic test properties.

## Missing data

For studies that did not report all of the statistical parameters and confidence intervals, wherever possible, the missing parameters and confidence intervals were derived from available information. Specifically, not all studies reported the elements of the two-by-two contingency tables, i.e., number of true-positive, false-positive, true-negative, and false-

negative. Unfortunately, these latter values are required for meta-analysis of diagnostic accuracy studies.

To derive the missing information, reviewers relied on the assumption that the elements of the two-by-two table can be recreated using available information, as described in the following paragraphs.

In most cases, sensitivity and specificity were provided without confidence intervals. In this situation the unique two-by-two table that would create the study's sensitivity and specificity can be estimated based on total study sample size. Occasionally, other outcome measures such as predictive values were provided, again without confidence intervals, and this information was used to verify the unique two-by-two table. Specifically, for a given study size, there is one unique set of two-by-two contingency table values that will create the sensitivity and specificity. The unique two-by-two contingency table will also create other diagnostic test performance estimates such as predictive values or likelihood ratios. If these latter values were reported in the published papers, reviewers could confirm that the unique two-by-two contingency table created these latter values.

When confidence intervals were provided, reviewers assumed they were derived through binomial approximation methods, which is the most common statistical distribution. From the available estimate and confidence interval, reviewers iteratively estimated the unique number of true-positives and false-negatives to recreate the confidence interval. After a similar exercise for non-disease cases, the numbers of true-negatives and false-positives were derived.<sup>17</sup> With these derived two-by-two table estimates, the estimates and confidence intervals were recreated to ensure approximate consistency, as well as being verified with other estimates such as positive predictive values. Studies that reported estimates with insufficient decimal places (e.g., sensitivity = 0.94 instead of 94.4%) led to the creation of a range of possible values in the two-by-two table, which can lead to inconsistencies between the derived two-by-two table and that in the original study. To minimize such discrepancies, the mean estimated values of the two-by-two estimates were used.

### **3.5.2 Economic review**

Only one economic study was identified in the search, therefore no pooling of results was completed. A narrative review of this economic evaluation was conducted.

## 4. Summary of Clinical Evidence

### 4.1 Quantity of Research Available

A total of 3,236 potential citations were identified by the clinical search, with 3,184 citations being excluded during the title and abstract review based on irrelevance to the questions of interest. The full text documents of the remaining 52 articles were retrieved. Of those, 41 did not meet the eligibility criteria and were excluded, and one reported cost-effectiveness data, leaving 10 articles for the clinical review.<sup>18-25</sup> The review identified one relevant systematic review that studied the value of ESR and CRP tests in diagnosis of inflammatory bowel diseases.<sup>26</sup> Of the 24 studies included in the aforementioned review, only one<sup>24</sup> evaluated the combination of ESR and CRP tests and compared the results with those of ESR and CRP alone. This study had already been identified and included in the review. A PRISMA diagram demonstrating the study selection process is presented in Appendix 7. A list of included and excluded studies is provided in Appendix 8.

### 4.2 Summary of Study Characteristics

A summary of individual study characteristics is presented in Appendix 9. Four of the included articles reported on the diagnostic performance of the study tests in diagnosing periprosthetic infections after total hip or knee arthroplasty procedures in adults.<sup>18,21,23,25</sup> Two studies reported on the diagnostic performance of ESR and CRP, individually and in combination, in pediatric orthopedic infections;<sup>20,22</sup> one study in pediatric bronchiolitis;<sup>27</sup> one study in inflammatory bowel diseases;<sup>24</sup> and two studies in giant cell arteritis.<sup>19,28</sup> The included studies originated from the US (6 studies),<sup>18,19,21,23,25,28</sup> the UK (2 studies),<sup>20,24</sup> Poland (one study),<sup>27</sup> and Finland (one study).<sup>22</sup>

Eight of the included studies were observational diagnostic accuracy studies. Of these, five used a prospective data collection approach,<sup>18,21-23,27</sup> while three reviewed medical charts retrospectively.<sup>19,20,25</sup> Two studies used a case-control design; in one, a group of undifferentiated patients (suspected inflammatory bowel disorder) who underwent both ESR and CRP tests along with the study's reference standard (barium flow) were compared with disease-positive and healthy control groups.<sup>24</sup> However, it was not clear how the data from the control groups were used in the analysis. Healthy controls in this study did not appear to undergo ESR and CRP testing. The second case-control study compared ESR and CRP test results from patients with a positive reference standard test (temporal artery biopsy) with those of the healthy control group.<sup>28</sup> One of the prospective diagnostic studies, which included children with suspected bronchiolitis, classified study participants into two subgroups — children with symptoms of viral respiratory infections and children with symptoms of bacterial respiratory infections — to perform an internal case-control-type analysis.<sup>27</sup> Sample sizes varied across the studies, ranging from 63<sup>24</sup> to 764<sup>19</sup> participants, mostly derived from individual academic hospitals. One study enrolled patients from multiple referral centres,<sup>22</sup> while the remaining seven studies were conducted in a single medical centre.

In the selected studies, different definitions were used for the combination of ESR and CRP tests. Three studies<sup>18,21,25</sup> reported the results for both ESR + CRP and ESR/CRP test combinations, while four other studies reported the results for ESR + CRP as the test combination option.<sup>19,20,24,28</sup> The definition of a combined test was not clear in the remaining three studies.<sup>22,23,27</sup> However, a closer examination of the results of two of these studies revealed that what had been considered a combined test in both studies had a higher sensitivity and lower specificity than either of the individual tests.<sup>23,22</sup> This likely reflects positive results if

either ESR or CRP is positive, i.e., the ESR/CRP combination. Accordingly, the data on the combined test from these two studies were assumed to reflect the ESR/CRP and were analyzed as such. The definition of the combined test in the third study remained unclear.<sup>27</sup>

## 4.3 Summary of Critical Appraisal

### 4.3.1 Risk of bias

Appendix 10 summarizes the results of the QUADAS-2 assessments. Three of the studies were rated as having a high risk of selection bias because they used a case-control design,<sup>24,28</sup> or applied extensive exclusion criteria.<sup>22,24</sup> In seven studies<sup>18-21,23,25,27</sup> it was unclear whether the recruitment approach or exclusion criteria could have introduced any selection bias; five of these studies included patients only if they had both ESR and CRP test results;<sup>18-21,23</sup> five excluded patients who were at a higher<sup>22</sup> or lower<sup>18</sup> risk of having the study outcome, or those with concurrent conditions that might have affected their ESR or CRP levels;<sup>23,25,27</sup> and three used a retrospective data collection approach.<sup>19,20,25</sup> The possibility of low generalizability of findings due to the study's sampling or site selection approach was discussed by the authors in two studies.<sup>19,22</sup>

None of the studies reported blinding of the results of ESR and CRP at the time of determining the final diagnosis, or provided specific information to assess whether knowledge of the reference standard might have influenced interpretation of index test results. Only one study<sup>19</sup> mentioned the time interval between ESR and CRP tests and the reference standard. Another study<sup>20</sup> was considered to be at a high risk of bias for index test and reference standard domains, due to not using pre-specified cut-off points for index tests (i.e., ESR and CRP) and using an imperfect reference standard (i.e., history of relevant clinical presentation, referral to an orthopedic team, and antibiotic therapy) for verification of final diagnosis. It was unclear if the reference standard used in one of the studies could correctly classify the target condition.<sup>19</sup> In this study, positive giant cell artery biopsy results were used for confirmation of diagnosis of giant cell arteritis. The authors noted in their discussion that the possibility of misclassification of biopsy-negative giant cell arteritis patients as disease-free could not be precluded in their study.

Three studies were assessed as being at unclear risk of bias for the flow and timing domain.<sup>22,24,27</sup> The study by Paakkonen et al.<sup>22</sup> seemed to combine microbiological culture results from joint and bone aspirations with different imaging modalities, such as ultrasound, radiographs, or magnetic resonance imaging, to make the final diagnosis of various osteoarticular infections. The schedules of measuring ESR and CRP were reported to be slightly different in this study. Grzesk et al.<sup>27</sup> used chest X-ray findings along with white blood cell count, bacteriologic tests, and clinical symptoms as the reference standard. However, their description of study methodology implied that chest X-ray and bacteriologic examination had not been performed for all study participants. The study by Hayreh et al.<sup>28</sup> was considered to be at a high risk of bias for the flow and timing domain because a subset of patients who were recruited prior to 1985 did not receive a CRP test. Therefore, diagnostic performance of ESR was estimated using data from all patients, whereas diagnostic performance measures for CRP and combined ESR and CRP testing were estimated in a smaller set of study participants. The timing of the ESR and CRP tests was not clearly indicated in the case-control diagnostic study by Dolwani et al.<sup>24</sup>

### 4.3.2 Applicability

Overall, applicability concerns related to patient selection, index test, and reference standard domains were low for the majority of included studies. To be rated as applicable to the research

question, the studies evaluated using the QUADAS-2 tool should have included the same patient population, index tests (ESR and CRP), and reference standard as defined in this review's study questions. Since the objective of this review was to compare a combination of ESR and CRP with either ESR or CRP for diagnosis of severe infectious and inflammatory disorders, reviewers decided that any reference standard that could provide a basis for accurate diagnosis would be applicable. One study,<sup>20</sup> which used retrospectively collected data on a combination of clinical symptoms, referral history, and antibiotic therapy to verify the diagnosis of pediatric bone and joint infections, was classified as raising some levels of applicability concern in terms of reference standard test. It was also unclear if the exclusion of culture (reference standard)-negative patients in the Paakkonen et al.<sup>22</sup> study could raise any applicability concerns in terms of patient selection. The possibility of low generalizability of findings due to the study's sampling or site selection approach was noted by the authors in two studies.<sup>19,22</sup> In addition, the generalizability of study results could be limited due to unusually high prevalence of disease in studies by Costa et al.<sup>18</sup> and Johnson et al.,<sup>21</sup> which can be ascribed to the referral nature of the study settings.

## 4.4 Summary of Findings

### 4.4.1 Diagnostic performance of ESR and CRP, when performed individually and in combination, for diagnosis of different conditions

An overview of the diagnostic performance of ESR, CRP, ESR + CRP, and ESR/CRP testing from the available studies is presented in Appendices 11 and 12. Appendix 11 provides details of the study index tests, the reference standard used for the confirmation of diagnosis, the relative frequency of disease-positive individuals diagnosed by the reference standard, and the number of truly or falsely diagnosed patients by the index tests of interest. Appendix 12 shows the diagnostic performance measures for the tests of interest when compared with the reference standard employed in each study (direct comparisons). Included studies are categorized by the studies' target conditions into four categories: periprosthetic infections; pediatric orthopedic infections; inflammatory bowel diseases; and giant cell arteritis.

#### Periprosthetic infections

Four studies used ESR (at the threshold of > 30 mm per hour and CRP (at the threshold of > 10 mg per litre), individually and in combination, for the diagnosis of periprosthetic infections.<sup>18,21,23,25</sup> Two of these studies used a single criterion of a positive synovial fluid bacterial culture as the reference standard,<sup>18,23</sup> while the other two employed similar multiple criteria diagnostic tools to confirm the diagnosis (see Appendix 11 for details). The prevalence of periprosthetic infection was considerably higher in the studies by Costa et al. (89.61%)<sup>18</sup> and Johnson (84.07%)<sup>21</sup> than the two other studies (39.19%<sup>23</sup> and 29.50%<sup>25</sup>). As shown in Appendix 12, among the four studies, the sensitivity and specificity of ESR ranged from 0.89<sup>18</sup> to 0.94<sup>25</sup> and from 0.33<sup>21</sup> to 0.72,<sup>23</sup> respectively. The sensitivity of CRP varied between 0.91<sup>25</sup> and 0.95<sup>21</sup> and its specificity between 0.20<sup>21</sup> to 0.77.<sup>25</sup> Data on performance of ESR + CRP in periprosthetic infections were available from three studies,<sup>18,21,25</sup> which reported sensitivity values for ESR + CRP ranging from 0.84<sup>18</sup> to 0.89<sup>21</sup> and specificity values ranging from 0.29<sup>21</sup> to 0.75.<sup>18</sup> The sensitivity and specificity of ESR/CRP for periprosthetic infections ranged from 0.96<sup>23</sup> to 0.98,<sup>25</sup> and from 0.20<sup>18</sup> to 0.59,<sup>25</sup> respectively.

The results of direct pooled analyses of the tests of interest versus the reference standard employed in each study are provided in Table 4. Among the four types of tests, the highest sensitivity for the diagnosis of periprosthetic infections was found for ESR/CRP (0.96 [95% confidence interval (CI), 0.94 to 0.98]) and the highest specificity was found for ESR + CRP (0.85 [95% CI, 0.81 to 0.89]). The pooled analysis also showed that, when compared with the

reference standard, the overall diagnostic accuracy (ODA) of ESR + CRP (0.86 [95% CI, 0.83 to 0.89]) was slightly higher than that of ESR/CRP (0.82 [95% CI, 0.80 to 0.85]) and CRP (0.82 [95% CI, 0.79 to 0.84]); and ESR had the lowest overall accuracy (0.79 [95% CI, 0.76 to 0.81]) among all four types of tests, in diagnosis of periprosthetic infections.

**Table 4: Pooled Analysis of Data for Diagnostic Performance of ESR and CRP Individually and in Combination for the Diagnosis of Periprosthetic Infection**

Test	Number of Studies (Ref. #)	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)	LR (+) (95% CI)	LR (-) (95% CI)	AUC (95% CI)	ODA (95% CI)
<b>ESR</b>	4 (18,21,23,25)	0.92 (0.89, 0.94)	0.70 (0.66, 0.73)	0.69 (0.65, 0.73)	0.92 (0.89, 0.95)	3.01 (2.17, 4.17)	0.12 (0.11, 0.14)	0.806 (0.751, 0.860)	0.79 (0.76, 0.81)
<b>CRP</b>	4 (18,21,23,25)	0.93 (0.91, 0.96)	0.73 (0.70, 0.77)	0.72 (0.68, 0.76)	0.94 (0.91, 0.96)	3.51 (2.45, 5.04)	0.09 (0.08, 0.11)	0.833 (0.775, 0.891)	0.82 (0.79, 0.84)
<b>ESR+ CRP</b>	3 (18,21,23,25)	0.87 (0.83, 0.91)	0.85 (0.81, 0.89)	0.82 (0.77, 0.86)	0.90 (0.87, 0.93)	5.79 (4.27, 7.85)	0.15 (0.12, 0.19)	0.861 (0.784, 0.939)	0.86 (0.83, 0.89)
<b>ESR/ CRP</b>	4 (18,21,25)	0.96 (0.94, 0.98)	0.57 (0.53, 0.61)	0.74 (0.70, 0.78)	0.95 (0.92, 0.97)	3.18 (2.02, 5.02)	0.06 (0.05, 0.07)	0.828 (0.762, 0.894)	0.82 (0.80, 0.85)

AUC = area under the curve; CRP = C-reactive protein; CI = confidence interval; ESR = erythrocyte sedimentation rate; LR (+) = positive likelihood ratio; LR (-) = negative likelihood ratio; NPV = negative predictive value; ODA = overall diagnostic accuracy; PPV = positive predictive value; Ref. = reference.

### Pediatric orthopedic infections

Data on the diagnostic performance of the study tests in pediatric orthopedic infections were available from two studies.<sup>20,22</sup> However, due to the paucity of data and significant differences between the two studies in terms of study population, index test cut-off points, and the reference standard, pooled analysis was not conducted for this subgroup of included studies.

Robinson et al.<sup>20</sup> retrospectively included children less than 13 years of age who presented with atraumatic limb pain at the study hospital's emergency room. The authors presented the diagnostic performance results for ESR (at the threshold of > 12 mm per hour), CRP (at the threshold of > 7 mg/L), and ESR + CRP against the reference standard (defined as a documented history of referral to an orthopedic team, diagnosis of infection, and antibiotic therapy). In this study ESR was reported to have the highest sensitivity (0.88 [95% CI, 0.73 to 1.04]) and ESR + CRP to have the highest specificity (0.90 [95% CI, 0.86 to 0.94]) among the three study tests (Appendix 12). The test thresholds in this study were determined based on the receiver operating characteristic (ROC) curve analysis.

Paakkonen et al.<sup>22</sup> prospectively recruited non-immune-deficient children between the age of three months and 15 years, who were referred to multiple tertiary care centres in Finland with a suspected acute joint or bone infection. The diagnostic threshold was considered to be greater than 20 mm per hour for ESR, and greater than 20 mg/L for CRP. A positive bone or joint bacterial culture was the main diagnostic criteria (reference standard) used in this study. However, patients were excluded if they had a negative culture, which allowed only sensitivity values to be reported. This study demonstrated sensitivities of 0.94 (95% CI, 0.90 to 0.96), 0.95 (95% CI, 0.90 to 0.97), and 0.98 (95% CI, 0.96 to 0.99), for ESR, CRP, and ESR/CRP, respectively (Appendix 12).

## **Inflammatory bowel diseases**

Dolwani et al.<sup>24</sup> reported on the diagnostic performance of ESR, CRP, and ESR + CRP for diagnosis of inflammatory bowel conditions. This study was conducted in a mixed in-patient/outpatient population consisting of 63 unclassified/undifferentiated patients presenting with symptoms of inflammatory bowel disease, 25 patients with known active Crohn's disease, and 25 healthy controls. The study findings, however, seem to compare the diagnostic performance of ESR, CRP, and ESR + CRP with that of small bowel barium follow-through imaging (reference standard) in 63 undifferentiated cases. As shown in Appendix 12, ESR had the highest sensitivity (0.79 [95% CI, 0.60 to 1.00]) and ESR + CRP had the highest specificity (0.84 [95% CI, 0.73 to 0.94]). However, the overall accuracy of the three types of tests demonstrated little variation (between 0.70 and 0.76) in diagnosing inflammatory bowel diseases.

## **Giant cell arteritis**

Two studies evaluated the diagnostic value of ESR, CRP, and ESR + CRP for diagnosis of giant cell arteritis.<sup>19,28</sup> However, data were not pooled due to clinical and methodological heterogeneity in the studies. The two studies used different study designs and thresholds to define positive and negative test results. In one of the studies,<sup>28</sup> there was also intra-study variability in terms of number and characteristics of the patient population included in ESR and ESR + CRP comparison groups. Descriptions of the results from these two studies are discussed in the following paragraphs.

Kermani et al.<sup>19</sup> used ESR at the threshold of greater than 22 mm per hour for men and 29 mm per hour for women; CRP at the threshold of greater than 8 mg/L; and temporal artery biopsy as the gold standard. This study found sensitivity values of 0.84 (95% CI, 0.79 to 0.90), 0.86 (95% CI, 0.81 to 0.92), and 0.81 (95% CI, 0.75 to 0.87) for ESR, CRP, and ESR + CRP, respectively. ESR + CRP was reported to have a higher specificity (0.41 [95% CI, 0.37 to 0.45]) in detecting giant cell arteritis, compared with ESR (0.30 [95% CI, 0.26 to 0.33]) or CRP (0.31 [95% CI, 0.27 to 0.37]) alone.

The diagnostic case-control study by Hayreh et al.<sup>28</sup> used ESR at the threshold of greater than 10 mm per hour for men and 20 mm per hour for women; CRP at the threshold of greater than 5 mg/L; and temporal artery biopsy as the reference standard. The study included patients with suspected giant cell arteritis for whom temporal artery biopsy had been requested. All patients underwent ESR testing. However, a CRP test that became available midway through the study was used for study participants (cases and controls) who were recruited after this test became available (in 1985). The study found sensitivity values of 0.97 (95% CI, 0.92 to 0.99), 1.00 (95% CI, 0.93 to 1.00), and 0.98 (95% CI, 0.88 to 1.00) for ESR, CRP, and ESR + CRP, respectively. Specificity values were 0.67 (95% CI, 0.64 to 0.72), 0.82 (95% CI, 0.74 to 0.88), and 0.92 (95% CI, 0.86 to 0.96) for ESR, CRP, and ESR + CRP, respectively.

## **Pediatric bronchiolitis**

Grzesk et al.<sup>27</sup> studied the performance of ESR and CRP, when performed individually or in combination, in differentiating viral from bacterial bronchiolitis in children with clinical symptoms of bronchiolitis. The authors used ESR at the threshold of greater than 15 mm per hour; CRP at the threshold of greater than 15 mg/L; and chest X-ray findings in combination with white blood cell count of greater than 12 moles per litre and clinical symptoms as the gold standard. This study reported only AUC values as the diagnostic test performance measure. Lack of data reported on proportions of truly or falsely diagnosed cases did not allow for any calculations of sensitivity, specificity, and other diagnostic performance metrics. The authors reported AUCs of

0.71 (95% CI, 0.60 to 0.83) for ESR, 0.63 (95% CI, 0.51 to 0.75) for CRP, and 0.74 (95% CI, 0.60 to 0.88) for the combined ESR and CRP testing. The differences between the reported AUCs were not statistically significant, based on the overlapping confidence intervals.

#### 4.4.2 Comparative diagnostic performance of ESR and CRP, when performed individually and in combination for different conditions

The relative diagnostic performance of ESR, CRP, ESR + CRP, and ESR/CRP (indirect comparisons) is determined using the sensitivity and specificity, and ODA values from the included studies as demonstrated in Tables 5 to 8.

##### Periprosthetic infections

The relative performance measures calculated using pooled data from four studies<sup>18,21,23,25</sup> (Table 5) suggest that, for detection of periprosthetic infections, ESR + CRP can have statistically higher specificity than both ESR (relative specificity [RSpec] 1.21 [95% CI, 1.13 to 1.30]) and CRP (RSpec 1.16 [95% CI, 1.09 to 1.25]), and a statistically lower sensitivity than CRP (relative sensitivity [RSens] 0.94 [95% CI, 0.89 to 0.99]), but not ESR (RSens 0.95 [95% CI, 0.90 to 1.00]). The sensitivity of ESR/CRP was statistically higher than that of ESR (RSens 0.94 [95% CI, 1.01 to 1.08]) alone, and could be marginally higher than that of CRP (RSens 1.03 [95% CI, 1.00 to 1.07]). The results of this review's indirect comparisons suggest that, in terms of overall accuracy, ESR + CRP is more accurate than ESR alone (relative ODA 1.09 [95% CI, 1.04 to 1.14]) and can be equal to, if not better than, CRP (relative ODA 1.05 [95% CI, 1.00 to 1.10]). However, no statistically significant differences were found between ESR/CRP combination and individual results of either of ESR or CRP (Table 5).

**Table 5: Relative Diagnostic Performance of ESR and CRP Individually and in Combination for Diagnosis of Periprosthetic Infection (Four Studies)<sup>18,21,23,25</sup>**

Comparison	Relative Sensitivity (95% CI)	P value	Relative Specificity (95% CI)	P value	Relative ODA (95% CI)	P value
ESR + CRP vs. ESR	0.95 (0.90 to 1.00)	0.063	1.21 (1.13 to 1.30)	< 0.001	1.09 (1.04 to 1.14)	< 0.001
ESR + CRP vs. CRP	0.94 (0.89 to 0.99)	0.027	1.16 (1.09 to 1.25)	< 0.001	1.05 (1.00 to 1.10)	0.050
ESR/CRP vs. ESR	1.04 (1.01 to 1.08)	0.009	1.00 (0.93 to 1.08)	1.000	1.04 (0.99 to 1.09)	0.119
ESR/CRP vs. CRP	1.03 (1.00 to 1.07)	0.050	0.96 (0.89 to 1.03)	0.291	1.00 (0.96 to 1.04)	1.000

CI = confidence interval; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; ODA = overall diagnostic accuracy; vs. = versus.

##### Pediatric orthopedic infections

The limited evidence from two studies<sup>20,22</sup> in this category showed that, in diagnosis of pediatric orthopedic infections, ESR + CRP was statistically more specific than ESR (RSpec 1.36 [95% CI, 1.23 to 1.51]), but not CRP (RSpec 1.03 [95% CI, 0.98 to 1.03]). The sensitivity of ESR/CRP combination was statistically higher than that of ESR (RSens 1.04 [95% CI, 1.01 to 1.08]) and marginally higher than that of CRP (RSens 1.03 [95% CI, 1.00 to 1.07]). Data on specificity and overall accuracy of ESR/CRP was not available. ESR + CRP was shown to have a statistically

higher overall accuracy than ESR (relative ODA 1.31 [95% CI, 1.19 to 1.45]), but not CRP (relative ODA 1.02 [95% CI, 0.95 to 1.10]) (Table 6).

**Table 6: Relative Diagnostic Performance of ESR and CRP Individually and in Combination for Diagnosis of Pediatric Orthopedic Infections (Two Studies)<sup>20,22</sup>**

Comparison	Relative Sensitivity (95% CI)	P value	Relative Specificity (95% CI)	P value	Relative ODA (95% CI)	P value
ESR + CRP vs. ESR <sup>a</sup>	0.74 (0.50 to 1.12)	0.132	1.36 (1.23 to 1.51)	< 0.001	1.31 (1.19 to 1.45)	< 0.001
ESR + CRP vs. CRP <sup>a</sup>	0.92 (0.55 to 1.53)	0.751	1.03 (0.98 to 1.09)	0.244	1.02 (0.95 to 1.10)	0.585
ESR/CRP vs. ESR <sup>b</sup>	1.04 (1.01 to 1.08)	0.009	NR	NR	NR	NR
ESR/CRP vs. CRP <sup>b</sup>	1.03 (1.00 to 1.07)	0.050	NR	NR	NR	NR

CI = confidence interval; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; NR = not reported; ODA = overall diagnostic accuracy vs. = versus.

<sup>a</sup> Data for this comparison was available from the Robinson et al. study (one study).<sup>20</sup>

<sup>b</sup> Data for this comparison was available from the Paakkonen et al. study (one study).<sup>22</sup>

### Inflammatory bowel diseases

The relative measures of sensitivity, specificity, or ODA for ESR + CRP versus ESR or CRP alone for detecting inflammatory bowel conditions were estimated indirectly using data from a single identified study.<sup>24</sup> Data on diagnostic performance of ESR/CRP were not available from this study. As shown in Table 7, no statistically significant differences were found between ESR + CRP and either of the ESR or CRP tests, in terms of sensitivity, specificity, or ODA.

**Table 7: Relative Diagnostic Performance of ESR and CRP Individually and in Combination for Diagnosis of Inflammatory Bowel Disease (One Study)<sup>24</sup>**

Comparison	Relative Sensitivity (95% CI)	P value	Relative Specificity (95% CI)	P value	Relative ODA (95% CI)	P value
ESR + CRP vs. ESR	0.63 (0.36 to 1.13)	0.106	1.25 (0.99 to 1.60)	0.061	1.07 (0.88 to 1.34)	0.498
ESR + CRP vs. CRP	0.65 (0.34 to 1.16)	0.193	1.20 (0.96 to 1.50)	0.109	1.04 (0.85 to 1.28)	0.703
ESR/CRP vs. ESR	NR	NR	NR	NR	NR	NR
ESR/CRP vs. CRP	NR	NR	NR	NR	NR	NR

CI = confidence interval; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; NR = not reported; ODA = overall diagnostic accuracy; vs. = versus.

### Giant cell arteritis

The limited evidence from the two identified studies was used to indirectly determine relative diagnostic performance of ESR + CRP versus ESR or CRP tests alone. Data on diagnostic performance of ESR/CRP were not available from either of the studies reporting on giant cell arthritis. In both studies, ESR + CRP was statistically more specific than either ESR or CRP alone, and the sensitivity of the combined test was comparable to both individually interpreted ESR and CRP tests. However, due to heterogeneity in terms of study design and the diagnostic thresholds used for a positive test, the relative diagnostic measures are described separately for these two studies (see Tables 8 and 9 for details).

Based on review estimates, in the Kermani et al. study,<sup>19</sup> ESR + CRP was shown to have a statistically higher specificity than both ESR (RSpec 1.36 [95% CI, 1.17 to 1.60]) and CRP (RSpec 1.32 [95% CI, 1.14 to 1.54]) in diagnosis of giant cell arteritis. The sensitivity of the combined ESR + CRP test was comparable to both individually interpreted ESR and CRP test results (Table 8). In terms of overall diagnostic accuracy, ESR + CRP was found to be statistically more accurate than both ESR (relative ODA 1.19 [95% CI, 1.07 to 1.33]) and CRP (relative ODA 1.16 [95% CI, 1.05 to 1.29]).

**Table 8: Relative Diagnostic Performance of ESR (> 22 mm per Hour) and CRP (> 8 mg/L) Individually and in Combination for Diagnosis of Giant Cell Arteritis (One Study)<sup>19</sup>**

Comparison	Relative Sensitivity (95% CI)	P value	Relative Specificity (95% CI)	P value	Relative ODA (95% CI)	P value
ESR + CRP vs. ESR	0.96 (0.87 to 1.06)	0.416	1.36 (1.17 to 1.60)	< 0.001	1.19 (1.07 to 1.33)	0.001
ESR + CRP vs. CRP	0.94 (0.85 to 1.04)	0.228	1.32 (1.14 to 1.54)	< 0.001	1.16 (1.05 to 1.29)	0.004
ESR/CRP vs. ESR	NR	NR	NR	NR	NR	NR
ESR/CRP vs. CRP	NR	NR	NR	NR	NR	NR

CI = confidence interval; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; NR = not reported; ODA = overall diagnostic accuracy; vs. = versus.

In the study by Hyreh et al.<sup>28</sup>, CRP and ESR + CRP test results were not available for all study participants due to lack of availability of CRP test prior to 1985. Therefore, the relative sensitivity and specificity values were calculated for only ESR + CRP versus CRP alone. ESR + CRP was shown to have a statistically higher specificity (RSpec 1.12 [95% CI, 1.01 to 1.24]) and a comparable specificity (RSens 0.98 [95% CI, 0.91 to 1.05]), when compared with CRP alone in diagnosis of giant cell arteritis. In terms of overall diagnostic accuracy, ESR + CRP was found to be statistically more accurate than CRP (relative ODA 1.08 [95% CI, 1.01 to 1.26]) (Table 9).

**Table 9: Relative Diagnostic Performance of ESR (> 10 mm per Hour for Men and > 20 mm per Hour for Women) and CRP (> 5 mg/L) Individually and in Combination for Diagnosis of Giant Cell Arteritis (1 study)<sup>28</sup>**

Comparison	Relative Sensitivity (95% CI)	P value	Relative Specificity (95% CI)	P value	Relative ODA (95% CI)	P value
ESR + CRP vs. ESR	NR	NR	NR	NR	NR	NR
ESR + CRP vs. CRP	0.98 (0.91 to 1.05)	0.588	1.12 (1.01 to 1.24)	0.014	1.08 (1.01 to 1.26)	0.013
ESR/CRP vs. ESR	NR	NR	NR	NR	NR	NR
ESR/CRP vs. CRP	NR	NR	NR	NR	NR	NR

CI = confidence interval; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; NR = not reported; ODA = overall diagnostic accuracy; vs. = versus.

### Pediatric bronchiolitis

The study by Grzesk et al.<sup>27</sup> compared AUCs for the combined ESR and CRP testing versus either ESR or CRP alone used for differentiation of viral from bacterial bronchiolitis in a pediatric population. The study reported P values for the comparison of combined ESR and CRP testing

versus ESR alone and combined testing versus CRP alone to be 0.742 and 0.231, respectively.

## 5. Summary of Economic Evidence

### 5.1 Quantity of Research Available

One economic evaluation was identified that compared combined ESR and CRP testing with either test alone. This evaluation was a Japanese-based<sup>29</sup> study that evaluated the costs and number of “useful results” for a number of laboratory tests.

### 5.2 Summary of Critical Appraisal

The Drummond checklist<sup>30</sup> was used to critically appraise the one economic evaluation identified. Based on the checklist,<sup>30</sup> there were some deficiencies in the study design, as neither the perspective of the analysis nor justification of the form of economic evaluation were explicitly stated. As for data collection in the study, the authors did not provide a detailed definition of their clinical outcome being evaluated “useful result”. The authors did not undertake any sensitivity analysis as part of analysis of results. Additionally, no conclusions were provided on whether combined ESR + CRP testing is cost-effective compared with either test alone.

### 5.3 Summary of Findings

In their Japanese-based study of 177 outpatients, Takemura et al.<sup>29</sup> estimated the cost-effectiveness of a number of laboratory tests undertaken for suspected infection and inflammatory conditions. Two of the tests evaluated were ESR and CRP. The costs for each test were presented in Japanese Yen. The unit of effectiveness for the study was the proportion of tests that produced a “useful result”. The authors defined a “useful result” as a test result that contributed to a change in diagnosis or decision-making once the test result was taken into consideration. The cost per ESR and CRP test was reported to be ¥102.8 and ¥340.21, respectively. The proportion of test results that were found to be “useful” was 0.58 for combined ESR and CRP testing, 0.41 for ESR testing alone, and 0.53 for CRP testing alone. The authors reported the incremental cost-effectiveness of combined ESR and CRP testing compared with CRP testing alone be ¥1,737 per useful result produced. Though not presented in the study report, the incremental cost-effectiveness of combined ESR + CRP testing compared with ESR testing alone can be calculated as ¥2,001 per useful result produced. The cost per useful event can be converted from 2002 Japanese Yen to 2015 Canadian dollars by applying the historical 2002 exchange rate exchange rate<sup>31</sup> (1¥ = C\$0.012554) and inflating this to 2015 Canadian dollars using the Canadian Consumer Price Index health care component<sup>32</sup> (122.3 [January 2015 versus 2002]). Based on this conversion, the incremental cost of combined ESR + CRP testing compared with CRP alone and ESR alone can be estimated to be C\$26.67 per useful result and C\$30.72, respectively. The authors did not provide any conclusions about the cost-effectiveness of combined ESR + CRP testing compared with ESR or CRP alone.

Because the only identified published economic study was conducted in Japan, its generalizability to the Canadian setting is questionable. Furthermore, the outcome of “useful result” was not an outcome included in this review. Therefore, a primary economic evaluation was conducted to evaluate the cost-effectiveness of combined testing with ESR + CRP compared with either test alone using the diagnostic accuracy data collected in this review.

## 6. Primary Economic Evaluation

### 6.1 Methods

#### 6.1.1 Type of evaluation

A cost-effectiveness analysis was conducted to compare combined ESR + CRP testing with either ESR or CRP alone. The cost-effectiveness outcome evaluated depended on whether a positive combined test was based on **both** ESR and CRP being positive (ESR + CRP) or **either** ESR or CRP being positive (ESR/CRP).

If a combined positive test was based on both tests being positive (ESR + CRP), it was assumed that the benefit of a combined test compared with a single test would be to increase specificity and reduce the number of false-positive results. Therefore, the cost-effectiveness outcome for this definition was the incremental cost per false-positive avoided.

If a combined positive test was based on either test being positive (ESR/CRP), it was assumed that the benefit of a combined test compared with a single test would be to increase sensitivity and reduce the number of false-negative results. Therefore, the cost-effectiveness outcome for this definition was the incremental cost per false-negative avoided.

#### 6.1.2 Target population

There were a number of different target patient populations for this economic analysis. These were based on the patient populations in which comparative diagnostic accuracy data were found in the clinical review of this report. Specifically, the four target populations of the analyses were:

- patients suspected of periprosthetic infections
- children suspected of having orthopedic infections
- patients suspected of having inflammatory bowel diseases
- patients suspected of having giant cell arteritis.

As described in the clinical evaluation, because of the methodological differences in the two studies that evaluated giant cell arteritis,<sup>19,28</sup> pooling of diagnostic accuracy data was not completed. Therefore, two cost-effectiveness analyses were conducted for the giant cell arteritis population: one used the diagnostic accuracy and prevalence data from Kermani et al.,<sup>19</sup> while the other used diagnostic accuracy and prevalence data from Hayreh et al.<sup>28</sup>

#### 6.1.3 Comparators

The comparators in the evaluation are combined ESR and CRP testing; ESR testing alone; and CRP testing alone. In this analysis, pairwise comparisons of ESR + CRP versus ESR alone and ESR + CRP versus CRP alone were conducted. Because it was not intended to be part of this review, cost-effectiveness comparisons of ESR alone versus CRP alone were not reported.

#### 6.1.4 Perspective


A third-party payer perspective such as that of a provincial ministry of health was undertaken.

#### 6.1.5 Model structure

A graphical representation of the model structure is provided in Figure 1. The model begins with patients being tested for one of the conditions of the four target populations. There is an

underlying prevalence of disease that categorizes patients as either having the condition being tested for or not having the condition being tested for. Based on the test results, patients having the condition can either be diagnosed correctly as a true-positive or diagnosed incorrectly as a false-negative. Similarly, patients without the condition are either correctly diagnosed as a true-negative or incorrectly as a false-positive. The diagnostic status (i.e., true-positive, false-negative, true-negative, and false-positive) of patients is dependent on the prevalence of the disease, along with the sensitivity and specificity of the diagnostic test. As indicated in Figure 1, the proportion of false-positives can be calculated as 1 minus condition prevalence multiplied by 1 minus test specificity. Similarly, the proportion of false-negative results is calculated as condition prevalence multiplied by 1 minus the sensitivity of the test.

**Figure 1: Graphical Representation of the Model Structure**



ESR = erythrocyte sedimentation rate; CRP = C-reactive protein.

### 6.1.6 Clinical model inputs

As shown in Figure 1, to estimate the diagnosis status of patients for each testing strategy, the prevalence of the condition along with the sensitivity and specificity of each testing strategy are required. The prevalence rates used in the model for each of the four populations are shown in Table 10, and are based on the disease frequencies found in the included studies (see Appendix 11). The prevalence for the periprosthetic infection population was based on the weighted average disease frequency reported in the four studies evaluating this population.<sup>18,21,23,25</sup> For the pediatric orthopedic infections and the inflammatory bowel disease populations, there was only a single study in which disease frequency could be derived. For giant cell arteritis, prevalence rates specific to the studies by Kermani et al.<sup>19</sup> and Hayreh et al.<sup>28</sup> were used in the analysis.

**Table 10: Prevalence Rates by Population**

Population	Prevalence
Periprosthetic infection	0.422 <sup>18,21,23,25</sup>
Pediatric orthopedic infections	0.066 <sup>20</sup>
Inflammatory bowel disease	0.238 <sup>24</sup>
Giant Cell Arteritis	
Kermani	0.239 <sup>19</sup>
Hayreh	0.292 <sup>28</sup>

The sensitivity and specificity for each test strategy were based on the findings in the clinical review (see Appendix 12 and Table 4). Tables 11 and 12 present the sensitivity and specificity for each test by population. Table 4 shows data when a positive combined test is based on both ESR and CRP being positive. Table 5 shows diagnostic accuracy data when a combined test is defined as either ESR or CRP being positive. For the perioperative infection population, sensitivity and specificity are based on the pooled analysis in the clinical review (see Table 4). For the other populations, sensitivity and specificity were based on single studies (see Appendix 12). For giant cell arteritis, separate analyses were conducted based on data from by Kermani et al.<sup>19</sup> and Hayreh et al.<sup>28</sup> Data were available for only two populations when the combined test was based on either test being positive. For the pediatric infection population, Robinson et al.<sup>20</sup> informed diagnostic accuracy when the combined positive test was defined as both tests being positive, while Paakkonen et al.<sup>22</sup> informed data when the combined positive test was defined as when either test was positive.

**Table 11: Sensitivity and Specificity by Patient Population When a Positive Combined Test Assumes Both ESR and CRP Are Positive (ESR + CRP)**

Test	Periprosthetic Infection		Pediatric Orthopedic Infections		Inflammatory Bowel Disease		Giant Cell Arteritis Kermani et al. <sup>19</sup>		Giant Cell Arteritis Hayreh et al. <sup>28</sup>	
	sens	spec	sens	spec	sens	spec	sens	spec	sens	spec
ESR	0.92	0.70	0.88	0.66	0.79	0.67	0.84	0.30	0.97	0.67
CRP	0.93	0.73	0.71	0.87	0.77	0.7	0.86	0.31	1.0	0.82
ESR + CRP	0.87	0.85	0.65	0.90	0.50	0.84	0.81	0.41	0.98	0.92

CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; sens = sensitivity; spec = specificity.

**Table 12: Sensitivity and Specificity by Patient Population When a Positive Combined Test Assumes Either ESR or CRP is Positive (ESR/CRP)**

Test	Periprosthetic Infection		Pediatric Orthopedic Infections	
	sens	spec	sens	spec
ESR	0.92	0.70	0.94	NR
CRP	0.93	0.73	0.95	NR
ESR/CRP	0.96	0.57	0.98	NR

CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; sens = sensitivity; spec = specificity; NR = not reported.

### 6.1.7 Resource use and costs

CADTH conducted a survey to estimate the costs of ESR and CRP testing across Canada. At least one contact in each jurisdiction was asked to complete the survey. Contacts were asked the cost of each test, and to indicate the various components included in the test costs, along with utilization data. A summary of the survey results is presented in Table 13. As shown, there was much variation in the reported test costs and included components. For example, the cost of CRP was reported to be \$0.67 in New Brunswick, \$1.60 in Nunavut, and \$10.31 in British Columbia. Much of this variation may have been due to differences in the components included in the cost estimates. For example, only the reagent costs were included in New Brunswick and Nunavut's CRP costs. Because of this variation, the costs of the tests in the model were assumed to be that reported by British Columbia, where it was reported that all components were included.

As such, the model assumed the cost of ESR and CRP to be \$10.61 and \$10.31, respectively. The cost of the combined test was assumed to be \$20.92, the sum of the individual ESR and CRP costs.

**Table 13: Results From Survey on Costs and Included Components of ESR and CRP Tests Across Jurisdictions in Canada**

Jurisdiction	ESR	Cost Includes	CRP	Cost Includes
Manitoba	Varies	Test, controls, and paper	\$1.15	Reagents, quality control, calibration
Yukon	\$10.72	Supplies and tech time	\$5.00	Cost of test
<b>British Columbia</b>	<b>\$10.61</b>	<b>All cost factors</b>	<b>\$10.31</b>	<b>All cost factors</b>
Saskatchewan	\$1.47	Technologist time, pipet	\$3.13	Reagents, controls, calibrators
Nunavut	\$ 1.14	Supplies only	\$1.60	Reagent only
New Brunswick	\$1.50	Reagent/collection container	\$0.67	Reagent only

Another source of data for test costs was provincial benefit schedules, which indicated fees for both ESR and CRP. Table 14 shows costs derived from these fee schedules, along with average fees of \$5.83 for ESR and \$9.57 for CRP. The cost of combined testing (\$15.40) was assumed to be the sum of the individual test costs. These alternative costs were assumed in sensitivity analysis.

**Table 14: Costs of ESR and CRP Across Provinces**

Province	ESR	CRP	ESR + CRP
British Columbia <sup>33</sup>	\$10.61	\$10.31	\$20.92
Alberta <sup>34</sup>	\$3.72	\$9.69	\$13.41
Saskatchewan <sup>35</sup>	\$10.00	\$16.00	\$26.00
Manitoba <sup>36</sup>	\$3.25	\$8.75	\$12.00
Ontario <sup>37</sup>	\$1.55	\$3.10	\$4.65
Average	\$5.83	\$9.57	\$15.40

CRP = C-reactive protein; ESR = erythrocyte sedimentation rate.

### 6.1.8 Sensitivity analysis

Sensitivity analyses were conducted on all variables that affected the model. Specifically, one-way sensitivity analyses were conducted on the incremental cost of the combined test, the diagnostic accuracy (sensitivity and specificity) of the test strategies, and the prevalence of conditions for the four different populations. The model was run using alternative testing costs based on the average from various provincial fee schedules. For diagnostic accuracy the model was run using the lower and upper confidence intervals for sensitivity and specificity. Similarly, the model was run using the lower and upper confidence intervals for the prevalence of the condition for each population. In addition, prevalence rates for all conditions varied from 0.01 to 0.95, due to the concern that prevalence rates from the reported studies may not reflect those found in clinical practice.

## 6.2 Results

### 6.2.1 Base-case results

#### Periprosthetic infection

Tables 15 and 16 present cost-effectiveness results for the periprosthetic infection population when the combined positive test is defined as ESR + CRP and ESR or CRP, respectively. False-positives and misdiagnoses are presented per 100 patients tested. As shown in Table 13, the number of false-positives per 100 patients tested for ESR, CRP, and ESR + CRP per patient are estimated to be 17.3, 15.6, and 8.7, respectively. This means a combined ESR + CRP would lead to 8.6 fewer false-positives per 100 patients tested than ESR alone and 6.9 fewer false-positives per 100 patients tested than CRP alone. When cost differences are taken into account, the incremental cost per false-positive avoided for ESR + CRP compared with ESR alone is estimated to be \$118.85. When compared with CRP alone, the cost per false-positive avoided is \$152.89. The cost per total misdiagnosis avoided for ESR + CRP is estimated to be \$157.02 and \$240.62, respectively.

**Table 15: Cost-Effectiveness Results for Periprosthetic Infection Population, ESR + CRP**

Testing Strategy	Cost	False-Positives (per 100 Patients)	Total Misdiagnoses <sup>a</sup> (per 100 Patients)	\$/False-Positive Avoided	\$/Misdiagnosis <sup>a</sup> Avoided
ESR	\$10.61	17.3	20.7		
CRP	\$10.31	15.6	18.6		
ESR + CRP	\$20.92	8.7	14.2		
ESR + CRP vs. ESR	\$10.31	-8.6	-6.6	\$118.85	\$157.02
ESR + CRP vs. CRP	\$10.61	-6.9	-4.4	\$152.89	\$240.62

CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; vs. = versus.

<sup>a</sup> Total misdiagnoses = false-positives + false-negatives.

Table 16 presents cost-effectiveness results for the periprosthetic infection population when a combined positive test is defined as either ESR or CRP being positive (ESR/CRP). As shown under this assumption, ESR/CRP is estimated to produce 1.7 fewer false-negatives per 100 patients tested than ESR alone and 1.3 fewer false-negatives per 100 patients tested than CRP alone. The cost per false-negative avoided for ESR/CRP is estimated to be \$611.22 compared with ESR alone, and \$838.68 compared with CRP alone. ESR/CRP is dominated (higher costs, less effectiveness) by both ESR alone and CRP alone when all misdiagnoses are considered. The combined test leads to 5.6 more total misdiagnoses per 100 patients tested than CRP alone and 8.3 more misdiagnoses per 100 patients tested than CRP alone.

**Table 16: Cost-Effectiveness Results for Periprosthetic Infection Population, ESR/CRP**

Testing Strategy	Cost	False-Negatives (per 100 Patients)	Total Misdiagnoses <sup>a</sup> (per 100 Patients)	\$/False-Negative Avoided	\$/Misdiagnosis <sup>a</sup> Avoided
ESR	\$10.61	3.4	21.0		
CRP	\$10.31	3.0	18.3		
ESR/CRP	\$20.92	1.7	26.6		
ESR/CRP vs. ESR	\$10.31	-1.7	5.6	\$611.22	dominated
ESR/CRP vs. CRP	\$10.61	-1.3	8.3	\$838.68	dominated

CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; vs. = versus.

<sup>a</sup> Total misdiagnoses = false-positives + false-negatives.

### Pediatric orthopedic infections

Table 17 presents cost-effectiveness results for the pediatric orthopedic infection population, when the combined positive test is defined as both ESR and CRP being positive (ESR + CRP). As shown, the proportions of false-positives for ESR, CRP, and ESR + CRP per 100 patients are estimated to be 31.8, 12.1, and 9.3, respectively. This means a combined ESR + CRP would lead to 22.5 fewer false-positives per 100 patients tested than ESR alone and 2.8 fewer false-positives per 100 patients tested than CRP alone. When cost differences are taken into account, the incremental cost per false-positive avoided for ESR + CRP compared with ESR alone is estimated to be \$45.97. When compared with CRP alone, the cost per false-positive avoided is \$378.50. The cost per total misdiagnosis avoided for ESR + CRP is estimated to be \$49.29 and \$440.32, respectively.

**Table 17: Cost-Effectiveness Results for Pediatric Orthopedic Infections, ESR + CRP**

Testing Strategy	Cost	False-Positives (per 100 Patients)	Total Misdiagnoses <sup>a</sup> (per 100 Patients)	\$/False-Positive Avoided	\$/Misdiagnosis <sup>a</sup> Avoided
ESR	\$10.61	31.8	32.6		
CRP	\$10.31	12.1	14.0		
ESR + CRP	\$20.92	9.3	11.6		
ESR + CRP vs. ESR	\$10.31	-22.5	-20.9	\$45.97	\$49.29
ESR + CRP vs. CRP	\$10.61	-2.8	-2.4	\$378.50	\$440.32

CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; vs. = versus.

<sup>a</sup> Total misdiagnoses = false-positives + false-negatives.

Table 18 presents cost-effectiveness results for the pediatric orthopedic infection population, when a combined positive test is defined as either ESR or CRP being positive (ESR/CRP). ESR/CRP is estimated to produce 0.3 fewer false-negatives than ESR alone, and 0.2 fewer false-negatives than CRP alone. The cost per false-negative avoided for ESR/CRP is estimated to be \$3,929 compared with ESR alone and \$5,391.26 compared with CRP alone. Because specificity was not reported in the single study informing this analysis, total misdiagnoses could not be estimated.

**Table 18: Cost-Effectiveness Results for Pediatric Orthopedic Infections, ESR/CRP**

Testing Strategy	Cost	False-Negatives (per 100 Patients)	Total Misdiagnoses <sup>a</sup> (per 100 Patients)	\$/False-Negative Avoided	\$/Misdiagnosis <sup>a</sup> Avoided
ESR	\$10.61	0.4	NA		
CRP	\$10.31	0.3	NA		
ESR/CRP	\$20.92	0.1	NA		
ESR/CRP vs. ESR	\$10.31	-0.3	NA	\$3,929.12	NA
ESR/CRP vs. CRP	\$10.61	-0.2	NA	\$5,391.26	NA

CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; NA = not available; vs. = versus.

<sup>a</sup> Total misdiagnoses = false-positives + false-negatives.

### Inflammatory Bowel Disease

Table 19 presents cost-effectiveness results for the inflammatory bowel disease population when the combined positive test is defined as both ESR and CRP being positive (ESR + CRP). The proportions of false-positives for ESR, CRP, and ESR + CRP per 100 patients tested are estimated to be 25.1, 22.9, and 12.2, respectively. This means a combined ESR + CRP would lead to 12.9 fewer false-positives per 100 patients tested than ESR alone and 10.7 fewer false-positives per 100 patients tested than CRP alone. When cost differences are taken into account, the incremental cost per false-positive avoided for ESR + CRP compared with ESR alone is estimated to be \$79.60. When compared with CRP alone, the cost per false-positive avoided is \$99.47. The cost per total misdiagnosis avoided for ESR + CRP is estimated to be \$170.49 and \$250.36, respectively.

**Table 19: Cost-Effectiveness Results for Inflammatory Bowel Disease, ESR + CRP**

Testing Strategy	Cost	False-Positives (per 100 Patients)	Total Misdiagnoses <sup>a</sup> (per 100 Patients)	\$/False-Positive Avoided	\$/Misdiagnosis <sup>a</sup> Avoided
ESR	\$10.61	25.1	30.1		
CRP	\$10.31	22.9	28.3		
ESR + CRP	\$20.92	12.2	24.1		
ESR + CRP vs. ESR	\$10.31	-12.9	-6.0	\$79.60	\$170.49
ESR + CRP vs. CRP	\$10.61	-10.7	-4.2	\$99.47	\$250.36

CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; vs. = versus.

<sup>a</sup> Total misdiagnoses = false-positives + false-negatives.

### Giant Cell Arteritis

Table 20 presents cost-effectiveness results for patients suspected of having giant cell arteritis, using prevalence and diagnostic accuracy data from Kermani et al.<sup>19</sup> The proportion of false-positives for ESR, CRP, and ESR + CRP in this population are estimated to be 53.3, 52.5, and 44.9 per 100 patients tested, respectively. Therefore, a combined ESR + CRP would lead to 8 fewer false-positives per 100 patients tested than ESR alone and 7.6 fewer false-positives per 100 patients tested than CRP alone. When cost differences are taken into account, the incremental cost per false-positive avoided for ESR + CRP compared with ESR alone is estimated to be \$123.18. When compared with CRP alone, the cost per false-positive avoided is \$139.44. The cost per total misdiagnosis avoided for ESR + CRP is estimated to be \$134.73 and \$165.43, respectively.

**Table 20: Cost-Effectiveness Results for Giant Cell Arteritis, ESR + CRP (Kermani et al.<sup>19</sup>)**

Testing Strategy	Cost	False-Positives (per 100 Patients)	Total Misdiagnoses <sup>a</sup> (per 100 Patients)	\$/False-Positive Avoided	\$/Misdiagnosis <sup>a</sup> Avoided
ESR	\$10.61	53.3	57.1		
CRP	\$10.31	52.5	55.8		
ESR + CRP	\$20.92	44.9	49.4		
ESR + CRP vs. ESR	\$10.31	-8.4	-7.7	\$123.18	\$134.73
ESR + CRP vs. CRP	\$10.61	-7.6	-6.4	\$139.44	\$165.43

CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; vs. = versus.

<sup>a</sup> Total misdiagnoses = false-positives + false-negatives.

Table 21 presents cost-effectiveness results for patients suspected of having giant cell arteritis, using prevalence and diagnostic accuracy data from Hayreh et al.<sup>28</sup> The proportion of false-positives for ESR, CRP, and ESR + CRP in this population are estimated to be 23.4, 12.7, and 5.7 per 100 patients tested, respectively. Therefore, a combined ESR + CRP would lead to 17.7 fewer false-positives per 100 patients tested than ESR alone, and 7.1 fewer false-positives per 100 patients tested than CRP alone. When cost differences are taken into account, the incremental cost per false-positive avoided for ESR + CRP compared with ESR alone is estimated to be \$58.25. When compared with CRP alone, the cost per false-positive avoided is \$149.86. The cost per total misdiagnosis avoided for ESR + CRP is estimated to be \$57.30 and \$163.33, respectively.

**Table 21: Cost-Effectiveness Results for Giant Cell Arteritis, ESR + CRP (Hayreh et al.<sup>28</sup>)**

Testing Strategy	Cost	False-Positives (per 100 Patients)	Total Misdiagnoses <sup>a</sup> (per 100 Patients)	\$/False-Positive Avoided	\$/Misdiagnosis <sup>a</sup> Avoided
ESR	\$10.61	23.4	24.2		
CRP	\$10.31	12.7	12.7		
ESR + CRP	\$20.92	5.7	6.2		
ESR + CRP vs. ESR	\$10.31	-17.7	-18.0	\$58.25	\$57.30
ESR + CRP vs. CRP	\$10.61	-7.1	-6.5	\$149.86	\$163.33

CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; vs. = versus.

<sup>a</sup> Total misdiagnoses = false-positives + false-negatives.

## 6.2.2 Sensitivity analysis

Table 22 presents cost-effectiveness results using cost estimates derived from provincial benefit fee schedules. As shown, the incremental cost per false-positive avoided of the combined test compared with ESR alone is very similar, using the alternate cost source compared with the base-case assumption across the various populations. However, compared with CRP alone, the incremental cost per false-positive avoided is nearly half of what it is using the base-case assumption. A similar pattern emerges for the incremental cost per false-negative for ESR/CRP compared with ESR alone and CRP alone.

**Table 22: Sensitivity Analysis of Cost-Effectiveness Using Alternative Estimates for ESR (\$5.83), CRP (\$9.57), and Combined Testing (\$15.40), Based on Provincial Fee Schedules**

	Periprosthetic Infections		Pediatric Orthopedic Infections		Inflammatory Bowel Disease		Giant Cell Arteritis (Kermani et al. <sup>19</sup> )		Giant Cell Arteritis (Hayreh et al. <sup>28</sup> )	
	vs. ESR	vs. CRP	vs. ESR	vs. CRP	vs ESR	vs. CRP	vs. ESR	vs. CRP	vs. ESR	vs. CRP
<b>Test cost source</b>	Cost per false-positive avoided of ESR + CRP vs. ESR or CRP alone									
<b>Base case</b>	\$119	\$153	\$46	\$378	\$80	\$99	\$123	\$139	\$58	\$150
<b>Alternative costs (provincial fee schedules)</b>	\$110	\$84	\$43	\$208	\$74	\$55	\$114	\$77	\$54	\$82
<b>Test cost source</b>	Cost per false-negative avoided of ESR/CRP vs. ESR or CRP alone									
<b>Base case</b>	\$611	\$839	\$3,929	\$5,391						
<b>Alternative costs (provincial fee schedules)</b>	\$567	\$461	\$3,647	\$2,960						

CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; vs. = versus.

Cost-effectiveness results are shown in Table 23, where the lower and upper confidence intervals for sensitivity and specificity for the testing strategies are used in the model. The confidence intervals for sensitivity and specificity for each test by population were based on data provided in Appendix 12 and Table 4. As shown, varying the diagnostic accuracy produces small variations in the incremental cost per false-positive avoided for ESR + CRP in most populations. The cost per false-positive avoided was most affected in the giant cell arteritis population when using sensitivity and specificity estimates from Kermani et al.<sup>19</sup> More variation is seen for the incremental cost per false-negative avoided for ESR/CRP compared with ESR or CRP alone. In the pediatric orthopedic population, the cost per false-negative avoided for ESR/CRP compared with ESR alone is estimated to be \$2,619 when the lower confidence intervals for diagnostic accuracy for all test strategies are used. The cost per false-negative avoided is estimated to be \$5,239 if the upper 95% confidence intervals for diagnostic accuracy are used. The cost per false-negative avoided for ESR/CRP compared with CRP alone is estimated to be \$3,235 if the lower 95% confidence intervals for diagnostic accuracy are used as estimates for diagnostic accuracy. If the higher 95% confidence interval for sensitivity is used for all testing strategies, the incremental cost per false-negative avoided for ESR/CRP compared with ESR alone becomes \$8,087.

**Table 23: Sensitivity Analysis of Cost-Effectiveness Using Lower and Upper Confidence Intervals for Diagnostic Accuracy for All Testing Strategies**

	Periprosthetic Infections		Pediatric Orthopedic Infections		Inflammatory Bowel Disease		Giant Cell Arteritis (Kermani et al. <sup>19</sup> )		Giant Cell Arteritis (Hayreh et al. <sup>28</sup> )	
	vs. ESR	vs. CRP	vs. ESR	vs. CRP	vs. ESR	vs. CRP	vs. ESR	vs. CRP	vs. ESR	vs. CRP
<b>ESR + CRP diagnostic accuracy</b>	Cost per false-positive avoided of ESR + CRP vs. ESR or CRP alone									
<b>Base case</b>	\$119	\$153	\$46	\$378	\$80	\$99	\$123	\$139	\$58	\$150
<b>Lower CI</b>	\$119	\$167	\$42	\$378	\$68	\$93	\$123	\$139	\$66	\$125
<b>Upper CI</b>	\$111	\$153	\$50	\$378	\$97	\$139	\$452	\$697	\$61	\$187
<b>ESR/CRP diagnostic accuracy</b>	Cost per false-negative avoided of ESR/CRP vs. ESR or CRP alone									
<b>Base case</b>	\$611	\$839	\$3,929	\$5,391						
<b>Lower CI</b>	\$489	\$839	\$2,619	\$3,235						
<b>Upper CI</b>	\$611	\$1,258	\$5,239	\$8,087						

CI = confidence interval; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; vs. = versus.

Table 24 presents cost-effectiveness results when the lower and upper confidence intervals for prevalence of disease for each population are used in the model. Little variation in the cost per false-positive avoided is found for ESR + CRP. Lower prevalence leads to lower cost per false-positive avoided for all populations, as lower prevalence rates lead to more false-positive test results and therefore more false-positives avoided for ESR + CRP because of its higher specificity. Greater variation in costs is found in the incremental cost per false-negative avoided for ESR/CRP. Higher prevalence leads to lower cost per false-negative avoided for all populations, because higher prevalence rates lead to fewer false-negative test results and therefore fewer false-negatives avoided for ESR/CRP.

**Table 24: Sensitivity Analysis of Cost-Effectiveness Using Lower and Upper Confidence Intervals of Condition Prevalence**

	Periprosthetic Infections		Pediatric Orthopedic Infections		Inflammatory Bowel Disease		Giant Cell Arteritis (Kermani et al. <sup>19</sup> )		Giant Cell Arteritis (Hayreh et al. <sup>28</sup> )	
	vs. ESR	vs. CRP	vs. ESR	vs. CRP	vs. ESR	vs. CRP	vs. ESR	vs. CRP	vs. ESR	vs. CRP
<b>ESR + CRP prevalence data used</b>	Cost per false-positive avoided of ESR + CRP vs. ESR or CRP alone									
<b>Base case (mean)</b>	\$119	\$153	\$46	\$378	\$80	\$99	\$123	\$139	\$58	\$150
<b>Lower CI</b>	\$113	\$145	\$45	\$367	\$70	\$87	\$118	\$134	\$56	\$144
<b>Upper CI</b>	\$126	\$162	\$48	\$391	\$92	\$115	\$128	\$145	\$61	\$157
<b>ESR/CRP prevalence data used</b>	Cost per false-negative avoided of ESR/CRP vs. ESR or CRP alone									
<b>Base case (mean)</b>	\$611	\$839	\$3,929	\$5,391						
<b>Lower CI</b>	\$660	\$905	\$7,271	\$9,977						
<b>Upper CI</b>	\$569	\$781	\$2,692	\$3,694						

CI = confidence interval; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; vs. = versus.

Table 25 presents sensitivity analysis using the upper and lower 95% confidence intervals for both diagnostic accuracy and condition prevalence as model values for all testing strategies. As shown, there is not much difference in the cost per false-positive avoided for ESR + CRP between the lower and upper confidence sensitivity analysis, except in the giant cell arteritis population when diagnostic accuracy data from Kermani et al.<sup>19</sup> are used. There is also not much difference in the cost per false-negative of ESR/CRP versus either CRP or ESR alone between the lower and upper 95% confidence interval sensitivity analysis.

**Table 25: Sensitivity Analysis of Cost-Effectiveness Using Lower and Upper Confidence Intervals of Both Diagnostic Accuracy and Condition Prevalence**

	Periprosthetic Infections		Pediatric Orthopedic Infections		Inflammatory Bowel Disease		Giant Cell Arteritis (Kermani et al. <sup>19</sup> )		Giant Cell Arteritis (Hayreh et al. <sup>28</sup> )	
	vs. ESR	vs. CRP	vs. ESR	vs. CRP	vs. ESR	vs. CRP	vs. ESR	vs. CRP	vs. ESR	vs. CRP
<b>ESR + CRP prevalence and diagnostic accuracy data used</b>	Cost per false-positive avoided of ESR + CRP vs. ESR or CRP alone									
<b>Base case</b>	\$119	\$153	\$46	\$378	\$80	\$99	\$123	\$139	\$58	\$150
<b>Lower CI</b>	\$113	\$158	\$41	\$367	\$59	\$82	\$118	\$134	\$63	\$120
<b>Upper CI</b>	\$118	\$162	\$52	\$391	\$112	\$162	\$470	\$726	\$63	\$196
<b>ESR/CRP prevalence and diagnostic accuracy data used</b>	Cost per false-negative avoided of ESR/CRP vs. ESR or CRP alone									
<b>Base case</b>	\$611	\$839	\$3,929	\$5,391						
<b>Lower CI</b>	\$528	\$905	\$4,848	\$5,986						
<b>Upper CI</b>	\$569	\$1,172	\$3,589	\$5,540						

CI = confidence interval; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; vs.= versus.

## 7. Discussion

### 7.1 Summary of Main Findings

The systematic review of studies evaluating the diagnostic value of ESR and CRP tests, individually and in combination, for the diagnosis of suspected inflammatory conditions and severe infections included limited evidence from nine primary studies. Five patient populations to whom the study tests had been administered in the selected studies included adults with periprosthetic infections after total hip or knee arthroplasty, inflammatory bowel diseases, and giant cell arteritis, as well as children with orthopedic infections and those hospitalized with bronchiolitis. As would be expected, the results of this review indicated that ESR/CRP tests had consistently higher sensitivity values and lower specificity values relative to ESR and CRP tests alone. In contrast, sensitivity values of ESR + CRP tests were consistently lower and their specificity values were consistently higher than those of individual ESR and CRP tests. However, in this analysis, the performance of combined ESR and CRP tests (ESR + CRP or ESR/CRP) versus ESR and CRP alone varied across the conditions. The reviewers were unable to comment whether ESR or CRP had more positive results for the combined ESR/CRP. Most studies reported the number of tests where either ESR or CRP was positive without presenting the number of positive individual test results.

The results of this review showed that ESR + CRP was statistically more specific than both ESR and CRP ( $P$  values  $< 0.001$ ) in diagnosis of periprosthetic infections and giant cell arteritis, and more specific than ESR in the diagnosis of orthopedic infections in children ( $P$  value  $< 0.001$ ). In terms of relative sensitivity, the ESR/CRP combination was shown to be statistically superior to ESR ( $P$  value  $< 0.05$ ), and comparable, if not superior, to CRP ( $P$  value = 0.05) in diagnosis of periprosthetic infections in adults and orthopedic infections in children. This review's analysis revealed no statistical differences in diagnostic performance measures between ESR + CRP versus ESR and CRP alone in detecting inflammatory bowel diseases, and differentiating viral from bacterial bronchiolitis. The use of ESR and CRP tests in the single identified study on pediatric bronchiolitis<sup>27</sup> should be regarded merely as an application of these tests for research purposes and to enhance understanding about their diagnostic performance in this specific condition. The use of blood tests, of any kind, for routine diagnosis of bronchiolitis in children is not endorsed by either the Canadian Pediatric Society<sup>38</sup> or by other North American professional pediatric organizations such as the American Academy of Pediatrics.<sup>39</sup>

No data were available on ESR/CRP testing in inflammatory bowel diseases or giant cell arteritis. The variability found in this review's results could be attributed to the paucity of data and differences in study populations (eligibility criteria) or diagnostic thresholds.

The comparison of the estimates of ODA suggested that ESR + CRP could be significantly overall more accurate than both ESR and CRP tests for diagnosis of periprosthetic infections and giant cell arteritis, and overall more accurate than ESR, but not CRP, in diagnosis of orthopedic infections in children. No statistical differences were found between the ODA of ESR + CRP and that of ESR or CRP alone in inflammatory bowel diseases. It should be noted that a higher ODA estimate means that using the candidate test can result in more correctly diagnosed patients. The measure uses the absolute number of correctly diagnosed participants (TP + TN). In addition, ODA increases as disease prevalence decreases, but sensitivity and specificity remain unaffected.<sup>40</sup> Therefore, this measure should be interpreted considering other measures of diagnostic performance such as sensitivity, specificity, and predictive values. In addition, ODA increases as disease prevalence decreases, but sensitivity and specificity remain unaffected.<sup>40</sup>

One published economic evaluation<sup>29</sup> was identified that evaluated the cost-effectiveness of a combined test of ESR and CRP versus ESR and CRP alone. In this 2003 study the cost per useful result of combined ESR and CRP testing was found to be ¥1,737 (C\$26.67) compared with ¥2,001 (C\$30.72) for CRP alone. However, this was a Japanese-based study and the generalizability of results to the Canadian setting is questionable. Additionally, this review did not include “useful events” as an outcome. Therefore, a primary economic analysis was undertaken in which the cost-effectiveness outcomes were cost per false-positive avoided and cost per false-negative avoided, based on the diagnostic accuracy data and prevalence data collected as part of the clinical review.

In this review’s primary economic analysis, the base-case incremental cost per false-positive avoided for ESR + CRP compared with ESR alone ranged from \$46 for pediatric infections to \$123 for the detection of giant cell arteritis when using prevalence and diagnostic accuracy data from Kermani et al.<sup>19</sup> The incremental cost per false-positive avoided for ESR + CRP versus CRP alone ranged from \$99 for inflammatory bowel disease to \$378 for pediatric orthopedic infections. The cost-effectiveness varied across populations due to both differences in prevalence and due to the differences in added specificity of ESR + CRP versus either test alone.

The base-case cost per false-negative avoided for ESR/CRP was estimated to be \$611 compared with ESR alone and \$830 compared with CRP alone for the detection of perioperative infection. For the detection of pediatric infection, the base-case cost per false-negative of ESR/CRP was estimated to be \$3,929 compared with ESR alone and \$5,391 compared with CRP alone. The cost per false-negative avoided for ESR/CRP compared with either test alone was higher in the pediatric orthopedic infection population than in the periprosthetic infection population. This is likely due to differences in the assumed prevalence for these conditions. Cost-effectiveness results were very sensitive to the assumed prevalence of the condition in the population. For example, if the prevalence of pediatric infection in the tested population was 25%, the cost per false-negative avoided of CRP/ESR became \$1,289 and \$1,760 compared with ESR and CRP alone, respectively.

Drawing conclusions about whether combined testing is cost-effective based on this analysis is difficult. There are no common cost-effectiveness thresholds for the incremental cost per false-negative or false-positive avoided to reference. Furthermore, whether a cost per false test result is cost-effective is likely to differ across populations, as the consequences of a false test would also likely differ across populations.

## 7.2 Strengths and Limitations

This was a comprehensive review of available comparative evidence on accuracy of ESR, CRP, ESR + CRP, and ESR/CRP tests for diagnosis of inflammatory and infectious conditions. The review highlighted the limitations of the existing evidence by critically appraising the quality of the included studies. In addition to the direct comparison of the tests of interest to the reference standard employed in each study, this review also indirectly compared the relative accuracy of combined ESR and CRP testing with either ESR or CRP alone.

As with all research, this review has a number of limitations. Very few studies were identified for each condition. As a result, reviewers were not able to provide sufficient data and perform pooled analysis on the diagnostic performance of the study tests for various clinical conditions. Data from a larger number of studies would particularly be helpful to perform a more efficient indirect meta-analysis.<sup>41</sup> Additionally, the studies included in this systematic review were highly heterogeneous in terms of setting, prevalence of target condition, and inclusion criteria.

Therefore, reviewers were limited in drawing firm conclusions regarding if and when ESR and CRP tests should be used in combination for diagnosing inflammatory and infectious disorders.

The economic evaluation in this review also has limitations. The outcome of incremental cost per false test result (positive or negative) is intermediate and makes it difficult to draw conclusions on cost-effectiveness. In order to translate this into a more common cost-effectiveness outcome such as incremental cost per QALY, the cost and health consequences of both false-positives and false-negatives would need to be incorporated. These would differ according to the population being evaluated. Because of the large number of different potential populations, and a paucity of information regarding the populations for which there would be diagnostic data available, additional cost-effectiveness outcomes were not evaluated.

As well, the analysis was limited to pairwise comparisons of a combined testing strategy to ESR alone or CRP alone; cost-effectiveness analysis considering all three testing strategies simultaneously could not be performed. Therefore, conclusions of which of the three strategies (ESR alone, CRP alone, or combined testing) for a given willingness-to-pay threshold could not be made.

### **7.3 Generalizability of Findings**

The majority of the studies included in this review were performed in the US or UK and were mainly based in academic or referral hospitals. Although the results seem to be generalizable to other, similar centres, generalizability to general practice in Canada may be limited. In addition, the prevalence of the target conditions (e.g., periprosthetic infection) in some of the included studies was likely to be higher than would be seen in general practice. Thus, some of the results presented in this review are based on patient populations with high pre-test probabilities.

### **7.4 Other Considerations**

Overall diagnostic accuracy measures that were estimated based on the area under ROC curves indicated that ESR and CRP — regardless if they were conducted in pairs or individually — have a maximum overall diagnostic accuracy of 0.93. Therefore, these tests should not be relied on to rule in or rule out inflammatory or infectious conditions, and their results need to be considered in the context of other clinical findings. Further, the value of information gained by the combination of the two tests is highly dependent on clinical circumstances and decision-making contingent on the results. Recognizing that ESR + CRP increases specificity and the cost of sensitivity (and ESR/CRP has the opposite effect), there may be some additional, albeit limited, circumstances where sequential testing (as opposed to concurrent testing) would be desirable to improve a diagnostic property once specific results are known for the first test.

## References

1. Pagana KD, Pagana TJ, MacDonald S. *Mosby's Canadian manual of diagnostic and laboratory tests*. Toronto: Mosby Canada; 2013.
2. *CRP vs ESR assessing & measuring the inflammatory response*. Dunedin (New Zealand): bpac<sup>NZ</sup>; 2005 [cited 2015 Sep 21]. Available from: [http://www.bpac.org.nz/resources/campaign/crp\\_esr/crp\\_esr\\_poem.asp](http://www.bpac.org.nz/resources/campaign/crp_esr/crp_esr_poem.asp); [www.bpac.org.nz/resources/other/audits/bpac\\_crp\\_audit\\_wv.pdf](http://www.bpac.org.nz/resources/other/audits/bpac_crp_audit_wv.pdf)
3. Kushner I. *Acute phase reactants*. In: Furst DE, Romain PL, editors. UpToDate. Waltham, MA:2014 [cited 2014 Aug 8]. Available from: <http://www.uptodate.com>.
4. Morris SA. C-Reactive Protein (CRP): the best lab test for inflammation/infection. *Alberta Health Serv Lab Rep*. 2013 Apr 1 [cited 2015 Sept 28];3(1). Available from: <http://www.albertahealthservices.ca/LabServices/wf-lab-nls-2013-04-crp.pdf>
5. Chandrashekar S, Renuka P, Suresh KP. ESR or CRP, which inflammatory measure can accurately replace clinical measures in rheumatoid arthritis? *Ind J Rheumatol*. 2012;7(2):69-73.
6. Crowson CS, Rahman MU, Matteson EL. Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis. *J Rheumatol*. 2009;36(8):1606-10.
7. Watson J, Round A, Hamilton W. Raised inflammatory markers. *BMJ*. 2012;344:e454.
8. AHS Laboratory Services. C-reactive protein (CRP) and Erythrocyte Sedimentation Rate (ESR) Testing. *Alberta Health Serv Lab Bull*. 2014 Mar 19 [cited 2015 Sep 21]. Available from: <http://www.albertahealthservices.ca/LabServices/wf-lab-bulletin-esr-crp-testing.pdf>
9. Saenger A, Block D. *C-reactive protein and erythrocyte sedimentation rate testing: should both be ordered?* In: Utilization Spotlight. Rochester, MN: Mayo Medical Laboratories; 2012 Nov [cited 2014 Aug 8]. Available from: <http://www.mayomedicallaboratories.com/articles/communique/2012/11utiliz.html>.
10. Kainth MK, Gigliotti F. Simultaneous Testing of Erythrocyte Sedimentation Rate and C-Reactive Protein: Increased Expenditure without Demonstrable Benefit. *J Pediatr*. 2014 Jun 21.
11. Colombet I, Pouchot J, Kronz V, Hanras X, Capron L, Durieux P, et al. Agreement between erythrocyte sedimentation rate and C-reactive protein in hospital practice. *Am J Med*. 2010 Sep;123(9):863-13.
12. Gilmour D, Sykes AJ. Westergren and Wintrobe methods of estimating ESR compared. *Br Med J*. 1951 Dec 22 [cited 2015 Sep 11];2(4746):1496-7. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2070843/>
13. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med*. 2011;155(8):529-36.
14. Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. *Stat Med*. 2002;21(9):1237-56.
15. Wells GA, Sultan SA, Chen L, Khan M, Coyle D. *Indirect treatment comparison. Version 1.0 [computer program]*. Ottawa: CADTH; 2009.
16. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. *J Clin Epidemiol*. 1997;50(6):683-91.
17. *Imputing standard deviations*. In: Higgins JPT, Green S, editors, editors. *Cochrane handbook for systematic reviews of interventions 5.1.0 [updated March 2011]*. The Cochrane Collaboration; 2011. Chapter 16 [cited 2012 Oct 29]. Available from: <http://www.cochrane-handbook.org>.

18. Costa CR, Johnson AJ, Naziri Q, Maralunda GA, Delanois RE, Mont MA. Efficacy of erythrocyte sedimentation rate and C-reactive protein level in determining periprosthetic hip infections. *Am J Orthop*. 2012 Apr;41(4):160-5.
19. Kermani TA, Schmidt J, Crowson CS, Ytterberg SR, Hunder GG, Matteson EL, et al. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. *Semin Arthritis Rheum*. 2012 Jun;41(6):866-71.
20. Robinson S, Leonard P. C reactive protein, erythrocyte sedimentation rate, or both, in the diagnosis of atraumatic paediatric limb pain? *Emerg Med J*. 2012 Dec;29(12):969-71.
21. Johnson AJ, Zywiell MG, Stroh A, Marker DR, Mont MA. Serological markers can lead to false negative diagnoses of periprosthetic infections following total knee arthroplasty. *Int Orthop*. 2011 Nov;35(11):1621-6.
22. Paakkonen M, Kallio MJ, Kallio PE, Peltola H. Sensitivity of erythrocyte sedimentation rate and C-reactive protein in childhood bone and joint infections. *Clin Orthop Relat Res*. 2010 Mar;468(3):861-6.
23. Austin MS, Ghanem E, Joshi A, Lindsay A, Parvizi J. A simple, cost-effective screening protocol to rule out periprosthetic infection. *J Arthroplasty*. 2008 Jan;23(1):65-8.
24. Dolwani S, Metzner M, Wassell JJ, Yong A, Hawthorne AB. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. *Aliment Pharmacol Ther*. 2004 Sep 15;20(6):615-21.
25. Ghanem E, Antoci V, Jr., Pulido L, Joshi A, Hozack W, Parvizi J. The use of receiver operating characteristics analysis in determining erythrocyte sedimentation rate and C-reactive protein levels in diagnosing periprosthetic infection prior to revision total hip arthroplasty. *Int J Infect Dis*. 2009 Nov;13(6):e444-e449.
26. Jellema P, van Tulder MW, van der Horst HE, Florie J, Mulder CJ, van der Windt DA. Inflammatory bowel disease: a systematic review on the value of diagnostic testing in primary care. *Colorectal Dis*. 2011 [cited 2015 Sep 28];13(3):239-54. Available from: <http://onlinelibrary.wiley.com/doi/10.1111/j.1463-1318.2009.02131.x/abstract>
27. Grzesk E, Koltan S, Grzesk G, et al. Value of erythrocyte sedimentation rate, c-reactive protein and procalcitonin concentration versus multimarker strategy in management of bronchiolitis in pediatric emergency. *Med Biol Sci*. 2012;26.2:11-7.
28. Hayreh SS, Podhajsky PA, Raman R, Zimmerman B. Giant cell arteritis: validity and reliability of various diagnostic criteria. *Am J Ophthalmol*. 1997 Mar;123(3):285-96.
29. Takemura Y, Ishida H, Inoue Y. Utilization of common inflammatory markers in new, symptomatic, primary care outpatients based on their cost-effectiveness. *Clin Chem Lab Med*. 2003 May;41(5):668-74.
30. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. *BMJ*. 1996 Aug 3 [cited 2015 Mar 12];313(7052):275-83. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2351717/>
31. *Daily currency converter*. Ottawa: Bank of Canada; 2015. [cited 2015 Mar 12]. Available from: <http://www.bankofcanada.ca/rates/exchange/daily-converter/>
32. *Consumer Price Index, health and personal care, by province (monthly) (Newfoundland and Labrador)*. In: CANSIM, table 326-0020 and Catalogue nos. 62-001-X and 62-010-X. Ottawa: Statistics Canada; 2015 [cited 2015 Mar 19]. Available from: <http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/cpis13a-eng.htm>.
33. Medical Services Commission. *Laboratory medicine*. Victoria: Province of British Columbia; 2013 Aug 1. [cited 2014 Sep 8]. Available from: <https://www.health.gov.bc.ca/msp/infoprac/physbilling/payschedule/pdf/40-laboratory-medicine.pdf>

34. *Alberta Health Care insurance plan: medical procedure list as of 01 April 2014*. Edmonton: Government of Alberta; 2014 Apr 1. [cited 2014 Sep 8]. Available from: <http://www.health.alberta.ca/professionals/SOMB.html>
35. *Payment schedule for insured services provided by a physician*. Regina: Government of Saskatchewan; 2014 Apr 1. [cited 2014 Sep 8]. Available from: <http://www.saskatchewan.ca/government/health-care-administration-and-provider-resources/resources-for-health-care-businesses-and-career-development/physician-career-resources#physician-payment-schedules-newsletters-and-bulletins>
36. Minister of Health, Manitoba Health, Healthy Living and Seniors. *Manitoba physician's manual*. Winnipeg: Province of Manitoba; 2014 Apr 1. [cited 2014 Sep 8]. Available from: <http://www.gov.mb.ca/health/documents/physmanual.pdf>
37. Ontario Ministry of Health and Long-Term Care. *Schedule of benefits for laboratory services*. Toronto: Queen's Printer for Ontario; 1999 Apr 1. [cited 2014 Sep 8]. Available from: [http://www.health.gov.on.ca/english/providers/program/ohip/sob/lab/lab\\_services\\_sched\\_01\\_19990401.pdf](http://www.health.gov.on.ca/english/providers/program/ohip/sob/lab/lab_services_sched_01_19990401.pdf)
38. Friedman JN, Rieder MJ, Walton JM. Bronchiolitis: recommendations for diagnosis, monitoring and management of children one to 24 months of age. *Paediatr Child Health*. 2014 Nov [cited 2015 May 19];19(9):485-98. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235450/>
39. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. *Pediatrics*. 2014 Nov;134(5):e1474-502.
40. Eusebi P. Diagnostic accuracy measures. *Cerebrovasc Dis*. 2013;36(4):267-72.
41. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, et al. Indirect comparisons of competing interventions. *Health Technol Assess*. 2005 [cited 2013 Jul 15];9(26):1-134, iii-iv. Available from: <http://www.hta.ac.uk/execsumm/summ926.htm>
42. Simel DL, Samsa GP, Matchar DB. Likelihood ratios with confidence: sample size estimation for diagnostic test studies. *J Clin Epidemiol*. 1991;44(8):763-70.

# Appendix 1: Literature Search Strategy

OVERVIEW	
Interface:	National Library of Medicine
Databases:	PubMed <b>Note:</b> Subject headings have been customized for each database.
Date of Search:	June 11, 2014
Alerts:	Monthly search updates began June 11, 2014 and ran until August 2014.
Study Types:	Studies with diagnostic outcomes of interest and economic literature.
Limits:	Publication years 2004-June 2014 Humans
SYNTAX GUIDE	
[mesh]	Medical Subject Heading
[majr]	MeSH major topic
*	After a word, a truncation symbol (wildcard) to retrieve plurals or varying endings
[ti]	Title
[tiab]	Title or Abstract
[pt]	Publication type
[rn]	CAS registry number

SEARCH STRATEGY	
Line #	Search Strategy
<a href="#">#13</a>	Search <b>(#4 AND #7) NOT #10</b> Filters: <b>Publication date from 2004/01/01 to 2014/12/31; English</b>
<a href="#">#11</a>	Search <b>(#4 AND #7) NOT #10</b>
<a href="#">#12</a>	Search <b>(#4 AND #7) NOT #10</b> Filters: <b>English</b>
<a href="#">#10</a>	Search <b>#8 OR #9</b>
<a href="#">#9</a>	Search <b>((Animals[MESH] OR Animal Experimentation[MESH] OR "Models, Animal"[ MESH] OR Vertebrates[MESH]) NOT (Humans[MESH] OR Human experimentation[MESH])) OR (((animals[tiab] OR animal model[tiab] OR rat[tiab] OR rats[tiab] OR mouse[tiab] OR mice[tiab] OR rabbit[tiab] OR rabbits[tiab] OR pig[tiab] OR pigs[tiab] OR porcine[tiab] OR swine[tiab] OR dog[tiab] OR dogs[tiab] OR hamster[tiab] OR hamsters[tiab] OR chicken[tiab] OR chickens[tiab] OR sheep[tiab]) AND (publisher[sb] OR inprocess[sb] OR pubmednotmedline[sb])) NOT (human[ti] OR humans[ti] OR people[ti] OR children[ti] OR adults[ti] OR seniors[ti] OR patient[ti] OR patients[ti]))</b>
<a href="#">#8</a>	Search <b>editorial[pt] OR comment[pt] OR letter[pt] OR newspaper article[pt]</b>
<a href="#">#7</a>	Search <b>#5 OR #6</b>
<a href="#">#6</a>	Search <b>9007-41-4[rn] OR c-reactive protein*[tiab] OR creactive protein*[tiab] OR circulating reactive protein*[tiab] OR CRP[tiab] OR POC-CRP*[tiab] OR CRP-test*[tiab] OR POC-CRP-test*[tiab] OR hsCRP[tiab] OR hs-CRP[tiab]</b>
<a href="#">#5</a>	Search <b>C-Reactive Protein[majr]</b>
<a href="#">#4</a>	Search <b>#1 OR #2 OR #3</b>
<a href="#">#3</a>	Search <b>erythrocyte sedimentation*[tiab] OR erythrocyte sediment[tiab] OR blood sedimentation*[tiab] OR blood sediment[tiab]</b>
<a href="#">#2</a>	Search <b>westergren[tiab] OR Biernacki's reaction[tiab] OR ESR[tiab] OR ESR-test*[tiab] OR sed rate[tiab]</b>
<a href="#">#1</a>	Search <b>Blood Sedimentation[majr]</b>

## OTHER DATABASES

Cochrane Library Issue 6, 2014	Same MeSH, keywords, and date limits used as per Medline search, excluding study types and Human restrictions. Syntax adjusted for Cochrane Library databases.
-----------------------------------	--

## Grey Literature

Dates for Search:	June 2014
Keywords:	Included terms for erythrocyte sedimentation rate and c-reactive protein.
Limits:	Publication years 2004-present

Relevant websites from the following sections of the CADTH grey literature checklist, “Grey matters: a practical tool for evidence-based searching”

(<http://www.cadth.ca/en/resources/finding-evidence-is/grey-matters>) were searched:

- Health Technology Assessment Agencies
- Health Economics
- Clinical Practice Guidelines
- Databases (free)
- Internet Search

## Appendix 2: Title and Abstract Screening Checklist

Ref#: \_\_\_\_\_

Author: \_\_\_\_\_

Year: \_\_\_\_\_

<b>Population</b>	Any population
<b>Intervention</b>	a) Erythrocyte Sedimentation Rate (ESR) b) C-reactive Protein (CRP) c) A combination of ESR and CRP
<b>Comparator</b>	Any comparator
<b>Outcome</b>	Diagnostic performance measures <ul style="list-style-type: none"><li>• sensitivity</li><li>• specificity</li><li>• positive predictive value (PPV)</li><li>• negative predictive value (NPV)</li><li>• receiver operating characteristic curve (ROC)</li><li>• area under the curve (AUC)</li></ul>
<b>Study type</b>	Any study type

# Appendix 3: Full Text Screening Checklist

Ref#: \_\_\_\_\_

Author: \_\_\_\_\_

Year: \_\_\_\_\_

	Include	Exclude
<b>Population</b>	<input type="checkbox"/> Any undifferentiated population not being tested to monitor an existing condition	<ul style="list-style-type: none"> <li>• Studies without a defined population/condition</li> </ul>
<b>Intervention</b>	ESR and/or CRP used in combination: <input type="checkbox"/> ESR and CRP <input type="checkbox"/> ESR OR CRP	<ul style="list-style-type: none"> <li>• No results on the ESR and CRP test combination</li> <li>• ESR, CRP, and other test combinations (<math>\geq 3</math> tests)</li> </ul>
<b>Comparators</b>	<input type="checkbox"/> ESR or CRP alone	<ul style="list-style-type: none"> <li>• High-sensitivity CRP</li> <li>• ESR test performed using Wintrobe method</li> <li>• Tests that occur outside a central laboratory (e.g., in a physician's office)</li> <li>• Point-of-care tests</li> </ul>
<b>Outcomes</b>	<input type="checkbox"/> Diagnostic performance (sensitivity, specificity, PPV, NPV, AUC, ODA) <input type="checkbox"/> Cost-effectiveness (ICUR, ICER, other)	Clinical utility
<b>Study types</b>	<input type="checkbox"/> RCTs, prospective or retrospective observational (non-randomized) studies (cross-sectional, cohort, case-control)	Other types of study design (e.g., case reports)

AUC = area under the curve; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; ICER = incremental cost-effectiveness ratio; ICUR = incremental cost-utility ratio; NPV = negative predictive value; ODA = overall diagnostic accuracy; PPV = positive predictive value; RCT = randomized controlled trial; ROC = receiver operating characteristic curve.


Reason for exclusion: \_\_\_\_\_

## Appendix 4: QUADAS-2 Tool for the Quality Assessment of Diagnostic Accuracy Studies<sup>13</sup>

**State the review question:**

Patients (setting, intended use of index test, presentation, prior testing):
Index test(s):
Reference standard and target condition:

**Draw a flow diagram for the primary study:**



## Risk of bias and applicability judgments

### Domain 1: Patient selection

<b>A. Risk of bias</b>	
Describe methods of patient selection:	
Was a consecutive or random sample of patients enrolled?	Yes / No / Unclear
Was a case-control design avoided?	Yes / No / Unclear
Did the study avoid inappropriate exclusions?	Yes / No / Unclear
Could the selection of patients have introduced bias? Risk: Low / High / Unclear	
<b>B. Concerns regarding applicability</b>	
Describe included patients (prior testing, presentation, intended use of index test and setting):	
Is there concern that the included patients do not match the review question? Concern: Low / High / Unclear	

### Domain 2: Index test(s)

<b>A. Risk of bias</b>	
Describe the index test and how it was conducted and interpreted:	
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes / No / Unclear
If a threshold was used, was it pre-specified?	Yes / No / Unclear
Could the conduct or interpretation of the index test have introduced bias? Risk: Low / High / Unclear	
<b>B. Concerns regarding applicability</b>	
Is there concern that the index test, its conduct, or interpretation differ from the review question? Concern: Low / High / Unclear	
Were the index test results interpreted without knowledge of the results of the reference standard?	

### Domain 3: Reference standard

<b>A. Risk of bias</b>	
Describe the index test and how it was conducted and interpreted:	
Is the reference standard likely to correctly classify the target condition?	Yes / No / Unclear
Were the reference standard results interpreted without knowledge of the results of the index test?	Yes / No / Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Risk: Low / High / Unclear	
<b>B. Concerns regarding applicability</b>	
Is there concern that the target condition as defined by the reference standard does not match the review question? Concern: Low / High / Unclear	

## Domain 4: Flow and timing

<b>A. Risk of bias</b>	
Describe any patients who did not receive the index test(s) and/or reference standard or who were excluded from the 2x2 table (refer to flow diagram):	
Describe the time interval and any interventions between index test(s) and reference standard:	
<b>Was there an appropriate interval between index test(s) and reference standard?</b>	<b>Yes / No / Unclear</b>
<b>Did all patients receive a reference standard?</b>	<b>Yes / No / Unclear</b>
<b>Did patients receive the same reference standard?</b>	<b>Yes / No / Unclear</b>
<b>Were all patients included in the analysis?</b>	<b>Yes / No / Unclear</b>
<b>Could the patient flow have introduced bias?</b> <b>Risk: Low / High / Unclear</b>	

## Appendix 5: Clinical Data Abstraction Form

Study	
Ref ID	
Author	
Publication Year	
Country	
Funding	

Methodology	
Study design	
Setting	
Total sample size	
Condition(s) the tests are used for	
Other inclusion criteria	
Exclusion criteria	

Intervention/Comparator			
	ESR	CRP	Reference standard
Manufacturer			
Sample size			
Cut-off point(s) for a positive test			

Population Characteristics				
	ESR	CRP	ESR+CRP	Reference standard
Mean age, year (SD)				
Gender (% female)				
Ethnicity (% Caucasian)				
Concurrent conditions				
Other important variables (unit)				
1. _____ ( )				
2. _____ ( )				

<b>Results</b>					
<b>Outcome</b>	<b>CRP</b>	<b>ESR</b>	<b>ESR+CRP</b>	<b>ESR/CRP</b>	<b>P value (comparison)</b>
<b>Diagnostic test performance</b>					
<b>Total number tested</b>					
<b>No true-positives (%)</b>					
<b>No true-negatives (%)</b>					
<b>No false-positives (%)</b>					
<b>No false-negatives (%)</b>					
<b>Sensitivity (95% CI)</b>					
<b>Specificity (95% CI)</b>					
<b>Positive likelihood ratio (95% CI)</b>					
<b>Negative likelihood ratio (95% CI)</b>					
<b>Positive predictive value (95% CI)</b>					
<b>Negative predictive value (95% CI)</b>					
<b>Area under ROC Curve (95% CI)</b>					
<b>Overall diagnostic accuracy (95% CI)</b>					

## Appendix 6: Details of Outcome Measures for Assessment of Diagnostic Test Performance

		Reference standard		
		Positive (Disease +)	Negative (Disease –)	Total
Index test	Positive	TP	FP	TP+FP
	Negative	FN	TN	FN+TN
	Total	TP+FN	FP+TN	TP+FP+TN+FN

TP = True-positives; when the positive index test agrees with the positive reference standard.

FP = False-positives; when the positive index test disagrees with the negative reference standard.

FN = False-negatives; when the negative index test disagrees with the positive reference standard.

TN = True-negatives; when the negative index test agrees with the negative reference standard.

From this 2 x 2 table, several tests of diagnostic performance can be made with confidence intervals.<sup>42</sup>

**Sensitivity:** TP/(TP+FN): the proportion of persons with the disease who are correctly identified by a test, i.e., a test with a high sensitivity is useful for “ruling out” a disease if a person tests negative.

$$\text{Confidence interval: } p \pm Z * \sqrt{\frac{p*(1-p)}{TP + FN}}$$

**Specificity:** TN/(TN+FP): the proportion of persons without a disease who are correctly identified by a test. High specificity is important when the treatment or diagnosis is harmful to the patient.

$$\text{Confidence interval: } p \pm Z * \sqrt{\frac{p*(1-p)}{TN + FP}}$$

**Positive Predictive Value (PPV):** TP/(TP+FP): the proportion of patients with positive test results who are correctly diagnosed.

$$\text{Confidence interval: } p \pm Z * \sqrt{\frac{p*(1-p)}{TP + FP}}$$

**Negative Predictive Value (NPV):** TN/(TN+FN): the proportion of patients with negative test results who are correctly diagnosed.

Confidence interval:  $p \pm Z * \sqrt{\frac{p * (1 - p)}{TN + FN}}$

**Positive Likelihood Ratio (LR+):** Indicates how much more likely it is to get a positive test in the diseased as opposed to the non-diseased group.

Confidence interval:  $LR+ = \exp(\ln \frac{sensitivity}{1 - specificity} \pm 1.96 * \sqrt{\frac{1 - sensitivity}{TP} + \frac{specificity}{FP}})$

**Negative Likelihood Ratio (LR-):** Indicates how much more likely it is to get a negative test in the non-diseased as opposed to the diseased group.

Confidence interval:  $LR- = \exp(\ln \frac{1 - sensitivity}{specificity} \pm 1.96 * \sqrt{\frac{sensitivity}{FN} + \frac{1 - specificity}{TN}})$

### Receiver Operator Characteristic Curve Analysis

AUC analysis will be performed for the patient level analysis. Because the estimates of sensitivity and specificity will be constructed for the full patient population, only one estimate of sensitivity and one estimate of specificity will be generated. With only one estimate the sensitivity/specificity graphical methods to derive AUC are not applicable. Instead, the accepted method of estimating AUC will be determined by the nonparametric Wilcoxon approximation of the 2x2 table (which is statistically equivalent to the AUC generated with the trapezoid rule, and the Mann-Whitney U Test).

The degree of precision of the estimate of the AUC estimated will be reported by generating the standard error and 95% confidence interval around the estimate.

**Area Under the Curve (AUC):** Represents the probability that a randomly chosen diseased patient is correctly diagnosed with greater suspicion than a randomly chosen non-diseased patient.

$$\text{Wilcoxon AUC} = \frac{TN \times TP + 0.5 \times TN \times FN + 0.5 \times FP \times TP}{N_N \times N_A}$$

Standard error (Hanley and McNeil method):

$$SE(A) = \sqrt{\frac{A(1 - A) + (N_A - 1) * (Q_1 - A^2) + (N_N - 1) * (Q_2 - A^2)}{N_A * N_N}}$$

where A = AUC, area under the curve

$N_A$  = number of positive disease cases

$N_N$  = number of negative disease cases

$$Q1 = \frac{TN \times [TP^2 + TP \times FN + \frac{1}{3} \times FN^2] + FP \times [\frac{1}{3} \times TP^2]}{N_N \times N_A^2}$$

$$Q2 = \frac{FN \times [\frac{1}{3} \times TN^2] + TP \times [TN^2 + TN \times TP + \frac{1}{3} \times FP^2]}{N_A \times N_N^2}$$

**Example:**

Overall	CICA: D+	CICA: D-	Total
64 CT: + test	183	22	205
64 CT: - test	2	219	221
Total	185	241	426

TP = 183, FP= 22, FN = 2, TN = 219  
D+: disease positive, D-: disease negative (absent)

$$AUC = (219 \times 183 + 0.5 \times 219 \times 2 + 0.5 \times 22 \times 183) / (185 \times 241) = 0.9490$$


Similarly, Q1 = 0.9287, Q2= 1.5051, SE =0.0581.

$$95\% \text{ CI} = (0.9490 - 1.96 \times 0.0581, 0.9490 + 1.96 \times 0.0581) = (0.8351, 1)$$

Overall diagnostic accuracy: (TP/TN)/(TP+FP+TN+FN) The proportion of correctly classified patients among all study participants.

Confidence interval:  $p \pm Z * \sqrt{\frac{p*(1-p)}{TN + TP + FN + FP}}$

## Appendix 7: Selection of Included Studies



# Appendix 8: List of Included and Excluded Studies

## Included Studies

### Clinical review

- Costa CR, Johnson AJ, Naziri Q, Maralunda GA, Delanois RE, Mont MA. Efficacy of erythrocyte sedimentation rate and C-reactive protein level in determining periprosthetic hip infections. *Am J Orthop (Belle Mead NJ)*. 2012 Apr;41(4):160-5.
- Kermani TA, Schmidt J, Crowson CS, Ytterberg SR, Hunder GG, Matteson EL, et al. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. *Semin Arthritis Rheum*. 2012 Jun;41(6):866-71.
- Robinson S, Leonard P. C reactive protein, erythrocyte sedimentation rate, or both, in the diagnosis of atraumatic paediatric limb pain? *Emerg Med J*. 2012 Dec;29(12):969-71.
- Grzesk E, Koltan S, Grzesk G, et al. Value of erythrocyte sedimentation rate, c-reactive protein and procalcitonin concentration versus multimarker strategy in management of bronchiolitis in pediatric emergency. *Med Biol Sci*. 2012;26.2:11-7.
- Johnson AJ, Zywiol MG, Stroh A, Marker DR, Mont MA. Serological markers can lead to false negative diagnoses of periprosthetic infections following total knee arthroplasty. *Int Orthop*. 2011 Nov;35(11):1621-6.
- Paakkonen M, Kallio MJ, Kallio PE, Peltola H. Sensitivity of erythrocyte sedimentation rate and C-reactive protein in childhood bone and joint infections. *Clin Orthop Relat Res*. 2010 Mar;468(3):861-6.
- Ghanem E, Antoci V, Jr., Pulido L, Joshi A, Hozack W, Parvizi J. The use of receiver operating characteristics analysis in determining erythrocyte sedimentation rate and C-reactive protein levels in diagnosing periprosthetic infection prior to revision total hip arthroplasty. *Int J Infect Dis*. 2009 Nov;13(6):e444-e449.
- Austin MS, Ghanem E, Joshi A, Lindsay A, Parvizi J. A simple, cost-effective screening protocol to rule out periprosthetic infection. *J Arthroplasty*. 2008 Jan;23(1):65-8.
- Dolwani S, Metzner M, Wassell JJ, Yong A, Hawthorne AB. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. *Aliment Pharmacol Ther*. 2004 Sep 15;20(6):615-21.
- Hayreh SS, Podhajsky PA, Raman R, Zimmerman B. Giant cell arteritis: validity and reliability of various diagnostic criteria. *Am J Ophthalmol* 1997;123(3):285-96.

### Economic review

- Takemura Y, Ishida H, Inoue Y. Utilization of common inflammatory markers in new, symptomatic, primary care outpatients based on their cost-effectiveness. *Clin Chem Lab Med* 2003;41(5):668-74.

## Excluded Studies

### Irrelevant study population

- Jee WH, McCauley TR, Lee SH, Kim SH, Im SA, Ha KY. Sacroiliitis in patients with ankylosing spondylitis: association of MR findings with disease activity. *Magn Reson Imaging*. 2004 Feb; 22(2):245-50.
- Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. *Ann Rheum Dis*. 2005 Feb;64(2):196-201.
- Jung SY, Park MC, Park YB, Lee SK. Serum amyloid a as a useful indicator of disease activity in patients with ankylosing spondylitis. *Yonsei Med J*. 2007 Apr 30;48(2):218-24.

- Romero-Sanchez C, Robinson WH, Tomooka BH, Londono J, Valle-Onate R, Huang F, et al. Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis. *Clin Rheumatol*. 2008 Nov;27(11):1429-35.
- Gonzalez-Gay MA, Garcia-Unzueta MT, Gonzalez-Juanatey C, Miranda-Filloo JA, Vazquez-Rodriguez TR, De Matias JM, et al. Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. *Clin Exp Rheumatol*. 2008 Mar;26(2):311-6.
- Crowson CS, Rahman MU, Matteson EL. Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis. *J Rheumatol*. 2009 Aug;36(8):1606-10.
- de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid A protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. *Arthritis Rheum*. 2009 Nov 15;61(11):1484-90.
- Pongprasobchai S, Jianjaroonwong V, Charatcharoenwitthaya P, Komoltri C, Tanwandee T, Leelakusolvong S, et al. Erythrocyte sedimentation rate and C-reactive protein for the prediction of severity of acute pancreatitis. *Pancreas*. 2010 Nov;39(8):1226-30.
- Turner D, Mack DR, Hyams J, LeLeiko N, Otley A, Markowitz J, et al. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis. *J Crohns Colitis*. 2011 Oct;5(5):423-9.
- Ye M, Yu H, Yu W, Zhang G, Xiao L, Zheng X, et al. Evaluation of the significance of circulating insulin-like growth factor-1 and C-reactive protein in patients with chronic obstructive pulmonary disease. *J Int Med Res*. 2012;40(3):1025-35.

#### **Irrelevant study tests**

- Jeremiah Z, Leonard I, Ezinma A. Discordantly elevated Erythrocyte Sedimentation Rate (ESR) and depressed C-Reactive Protein (CRP) values in early diagnosis of pulmonary tuberculosis patients in Maiduguri, Nigeria. *Open J Blood Dis*. 2013;3(2):74-7. Available from: <http://www.scirp.org/journal/PaperInformation.aspx?paperID=33616>
- CRP vs ESR assessing & measuring the inflammatory response. Dunedin (New Zealand): bpacnz; 2005. Available from: [http://www.bpac.org.nz/resources/campaign/crp\\_esr/crp\\_esr\\_poem.asp](http://www.bpac.org.nz/resources/campaign/crp_esr/crp_esr_poem.asp); [www.bpac.org.nz/resources/other/audits/bpac\\_crp\\_audit\\_wv.pdf](http://www.bpac.org.nz/resources/other/audits/bpac_crp_audit_wv.pdf)
- Laboratory tests in general practice. Brussels: Belgian Health Care Knowledge Centre; 2007. Available from: <https://kce.fgov.be/publication/report/laboratory-tests-in-general-practice>
- Wang C, Ao Y, Fan X, Wang J, Cui G, Hu Y, et al. C-Reactive Protein and Erythrocyte Sedimentation Rate Changes After Arthroscopic Anterior Cruciate Ligament Reconstruction: Guideline to Diagnose and Monitor Postoperative Infection. *Arthroscopy*. 2014 May 23.
- Parikh M, Miller NR, Lee AG, Savino PJ, Vacarezza MN, Cornblath W, et al. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. *Ophthalmology*. 2006 Oct;113(10):1842-5.
- Kofla-Dlubacz A, Matusiewicz M, Krzystek-Korpaczka M, Iwanczak B. Correlation of MMP-3 and MMP-9 with Crohn's disease activity in children. *Dig Dis Sci*. 2012 Mar;57(3):706-12.
- Khan MH, Smith PN, Rao N, Donaldson WF. Serum C-reactive protein levels correlate with clinical response in patients treated with antibiotics for wound infections after spinal surgery. *Spine J*. 2006 May;6(3):311-5.
- Iyengar KP, Vinjamuri S. Role of 99mTc Sulesomab in the diagnosis of prosthetic joint infections. *Nucl Med Commun*. 2005 Jun;26(6):489-96.
- Ghanem E, Parvizi J, Burnett RS, Sharkey PF, Keshavarzi N, Aggarwal A, et al. Cell count and differential of aspirated fluid in the diagnosis of infection at the site of total knee arthroplasty. *J Bone Joint Surg Am*. 2008 Aug;90(8):1637-43.

- Costello F, Zimmerman MB, Podhajsky PA, Hayreh SS. Role of thrombocytosis in diagnosis of giant cell arteritis and differentiation of arteritic from non-arteritic anterior ischemic optic neuropathy. *Eur J Ophthalmol*. 2004 May;14(3):245-57.
- Bottner F, Wegner A, Winkelmann W, Becker K, Erren M, Gotze C. Interleukin-6, procalcitonin and TNF-alpha: markers of peri-prosthetic infection following total joint replacement. *J Bone Joint Surg Br*. 2007 Jan;89(1):94-9.
- Ayazi P, Mahyar A, Daneshi MM, Jahani HH, Pirouzi M, Esmailzadehha N. Diagnostic Accuracy of the Quantitative C-Reactive Protein, Erythrocyte Sedimentation Rate and White Blood Cell Count in Urinary Tract Infections among Infants and Children. *Malays J Med Sci*. 2013 Oct; 20(5):40-6.
- Schinsky MF, Della Valle CJ, Sporer SM, Paprosky WG. Perioperative testing for joint infection in patients undergoing revision total hip arthroplasty. *J Bone Joint Surg Am*. 2008 Sep;90(9):1869-75.
- Mondal SK, Nag DR, Bandyopadhyay R, Chakraborty D, Sinha SK. Neonatal sepsis: Role of a battery of immunohematological tests in early diagnosis. *Int J Appl Basic Med Res*. 2012 Jan;2(1):43-7.
- Korppi M. Non-specific host response markers in the differentiation between pneumococcal and viral pneumonia: what is the most accurate combination? *Pediatr Int*. 2004 Oct;46(5):545-50.
- Don M, Valent F, Korppi M, Canciani M. Differentiation of bacterial and viral community-acquired pneumonia in children. *Pediatr Int*. 2009 Feb;51(1):91-6.
- Ahmed Z, Ghafoor T, Waqar T, Ali S, Aziz S, Mahmud S. Diagnostic value of C- reactive protein and haematological parameters in neonatal sepsis. *J Coll Physicians Surg Pak*. 2005 Mar;15(3):152-6.

#### **Irrelevant outcomes**

- Houshian S, Seyedipour S, Wedderkopp N. Epidemiology of bacterial hand infections. *Int J Infect Dis*. 2006 Jul;10(4):315-9.
- Gonzalez-Juanatey C, Llorca J, Miranda-Filloo JA, Amigo-Diaz E, Testa A, Garcia-Porrúa C, et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. *Arthritis Rheum*. 2007 Mar 15;57(2):287-93.
- Kainth MK, Gigliotti F. Simultaneous Testing of Erythrocyte Sedimentation Rate and C-Reactive Protein: Increased Expenditure without Demonstrable Benefit. *J Pediatr*. 2014 Jun 21.
- Schwarzkopf R, Mikhael B, Wright E, Estok DM, Katz JN. Treatment failure among infected periprosthetic total hip arthroplasty patients. *Open Orthop J*. 2014;8:118-24.
- *Irrelevant Study Type*
- Azhar SS, Tang RA, Dorotheo EU. Giant cell arteritis: diagnosing and treating inflammatory disease in older adults. *Geriatrics*. 2005 Aug;60(8):26-30.
- Batlivala SP. Focus on diagnosis: the erythrocyte sedimentation rate and the C-reactive protein test. *Pediatr Rev*. 2009 Feb;30(2):72-4.
- da Mota LM, dos Santos Neto LL, de Carvalho JF. Autoantibodies and other serological markers in rheumatoid arthritis: predictors of disease activity? *Clin Rheumatol*. 2009 Oct;28(10):1127-34.
- Jellema P, van Tulder MW, van der Horst HE, Florie J, Mulder CJ, van der Windt DA. Inflammatory bowel disease: a systematic review on the value of diagnostic testing in primary care. *Colorectal Disease*. 2011;13(3):239-54.
- Looking back, looking forward: key messages 2005 - 2011. Dunedin (New Zealand): bpacnz; 2012. Available from: <http://www.bpac.org.nz/Report/2012/March/reminders.aspx>
- Guerado E, Cervan AM. Surgical treatment of spondylodiscitis. An update. *Int Orthop*. 2012 Feb;36(2):413-20.

## Appendix 9: Characteristics of Included Studies

Author, Year	Country	Study Design	Setting	Study Population		Mean Age	Gender (% female)	Target Condition
				N	Eligibility criteria			
<b>Costa, 2012<sup>18</sup></b>	US	Diagnostic accuracy (prospective)	Single hospital	77	Inclusion: Patients undergoing revision THA between 2000 and 2008 Exclusion: Not stated	61 years (19 to 89 range)	58.4%	Periprosthetic infection (after THA)
<b>Kermani, 2012<sup>19</sup></b>	US	Diagnostic accuracy (retrospective)	University hospital	764	Inclusion: Patients TAB between 2000 and 2008 Exclusion: Patients who did not have both ESR and CRP measured 6 weeks before TAB	72.7 years (9.27 SD)	65%	Giant cell arteritis
<b>Robinson, 2012<sup>20</sup></b>	UK	Diagnostic accuracy (retrospective)	Teaching hospital-pediatrics emergency room	259	Inclusion: Patients $\leq$ 13 years of age presenting with atraumatic limb pain who had both ESR and CRP measured at presentation Exclusion: Previous orthopedic infection, chronic recurrent multifocal osteomyelitis, fractures and chronic disease causing limb pain	NA	NA	Pediatric orthopedic infection
<b>Grzesk, 2012<sup>27</sup></b>	Poland	Diagnostic accuracy (prospective) Internal comparison of two subgroups	Single hospital	149	Inclusion: Children hospitalized with clinical presentation of bronchiolitis Exclusion: Bronchial asthma, cystic fibrosis, pulmonary bronchodysplasia, congenital heart diseases, abnormalities of chest and lung, history of treatment with bronchodilators and anti-inflammatory drugs, and gastro-esophageal reflux	7 months (1 to 24 range)	31.5%	Pediatric bronchiolitis
<b>Johnson, 2011<sup>21</sup></b>	US	Diagnostic accuracy (prospective)	Single hospital	113	Inclusion: Patients undergoing revision TKA between 2000 and 2007 Exclusion: Patients with strong evidence of an infected joint	61 years (28 to 89 range)	46%	Periprosthetic infection (after TKA)
<b>Paakkonen, 2010<sup>22</sup></b>	Finland	Diagnostic accuracy	Multiple referral	265	Inclusion: Patients 3 months to 15 years of age presenting with signs	NA	NA	Pediatric septic bone

Author, Year	Country	Study Design	Setting	Study Population			Target Condition	
				N	Eligibility criteria	Mean Age		Gender (% female)
		(prospective)	hospitals		and symptoms suggesting acute osteoarticular infection Exclusion: Culture-negative cases; less than 3 months of age; and immune deficient patients			and joint infection
<b>Ghanem, 2009<sup>25</sup></b>	US	Diagnostic accuracy (retrospective)	Single hospital	479	Inclusion: Patients undergoing revision THA between 2000 and 2005 Exclusion: Patients with comorbidities that could elevate ESR and CRP values, such as inflammatory diseases, chronic renal failure, hepatitis, active malignancy, or infection in other regions of the body	66 years (23 to 93 range)	53%	Periprosthetic infection (after THA)
<b>Austin, 2008<sup>23</sup></b>	US	Diagnostic accuracy (prospective)	University hospital	296	Inclusion: Patients undergoing revision TKA between 2000 and 2005, who had preoperative ESR and CRP tests and pre- or intraoperative cultures performed Exclusion: Patients with confounding factors that could elevate ESR and CRP values	66 years	57.8%	Periprosthetic infection (after TKA)
<b>Dolwani, 2004<sup>24</sup></b>	UK	Diagnostic accuracy (case-control design: 63 undifferentiated patients with 25 controls with active Crohn's and 26 healthy individuals)	University hospital	63	Inclusion: Outpatient or in-patient cases, presenting with abdominal pain and diarrhea, who underwent a small bowel barium follow-through test Exclusion: Patients with known malignancy, those on NSAIDs or steroids, known cases of celiac disease, severe cardiomyopathy, renal or hepatic impairment, significant psychiatric disease, and alcohol or drug dependency Patients with abnormal rigid sigmoidoscopy or positive stool culture were excluded from the "case" group	47 years (17 to 86 range)	68%	Prediction of abnormal small bowel radiology for inflammatory bowel diseases
<b>Hayreh,</b>	US	Diagnostic	University	363	Inclusion:	72 years	66%	Giant cell

Author, Year	Country	Study Design	Setting	Study Population			Target Condition	
				N	Eligibility criteria	Mean Age		Gender (% female)
1997 <sup>28</sup>		accuracy (case-control design: 363 cases and 749 controls)	hospitals and clinics	(total, ESR, sample) 223 (ESR and CRP sub-sample) <sup>c</sup>	Cases: Patients referred for temporal artery biopsy from 1973 to 1994 Controls: Otherwise healthy patients with non-arteritic anterior ischemic optic neuropathy or retinal nerve occlusion Exclusion: Patients with any systemic abnormalities that might elevate ESR or CRP values	(20 to 95 range)		arteritis

CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; NA = not available; NSAIDs = nonsteroidal anti-inflammatory drugs; SD = standard deviation; TAB = temporal artery biopsy; THA = total hip arthroplasty; TKA = total knee arthroplasty.

<sup>a</sup>CRP testing was available for a subset of patients who were recruited from 1985 to 1994 (n = 223).

## Appendix 10: Risk of Bias and Applicability in the Included Diagnosis Studies (Results of QUADAS-2 Quality Assessment)<sup>13</sup>

Study Author, Year	Risk of Bias			Applicability Concerns			Potential Issues	
	Patient Selection	Index Test	Reference Standard	Follow & Timing	Patient Selection	Index Test		Reference Standard
Costa, 2012 <sup>18</sup>	Unclear	L	L	L	H	L	L	<ul style="list-style-type: none"> <li>Not all of potentially eligible cases were included in the study.</li> <li>Cases with a lower likelihood of infection were excluded from ESR and CRP testing and, therefore, from the analysis.</li> <li>47% of the non-infected cases had other disorders elevating CRP results.</li> </ul>
Kermani, 2012 <sup>19</sup>	Unclear	L	Unclear	L	L	L	L	<ul style="list-style-type: none"> <li>Based on the author's discussion, there was a risk that patients with negative biopsy GCA had been misclassified as non-disease.</li> <li>Authors also stated that due to performing the study in a referral hospital, the study population might not be representative of all patients with GCA.</li> </ul>
Robinson, 2012 <sup>20</sup>	Unclear	H	H	L	H	L	Unclear	<ul style="list-style-type: none"> <li>Retrospective chart review: only patients who had blood test results recorded were included in the study.</li> <li>No pre-specified cut-off points were noted for ESR and CRP.</li> <li>No gold standard was used to confirm the final diagnosis. Therefore, the reference standard included a description of patient's complaint, and a history of referral to the orthopedic team, diagnosis of infection, and antibiotic therapy.</li> <li>It is unclear whether the reference test was interpreted independent of the index tests (ESR and CRP).</li> </ul>

Study Author, Year	Risk of Bias			Follow & Timing	Applicability Concerns			Potential Issues
	Patient Selection	Index Test	Reference Standard		Patient Selection	Index Test	Reference Standard	
Grzesk, 2012 <sup>27</sup>	L	L	L	Unclear	H	L	Unclear	<ul style="list-style-type: none"> <li>Not all of potentially eligible cases were included in the study.</li> <li>It is unclear whether the reference test was interpreted independent of the index tests (ESR and CRP).</li> <li>Broad exclusion criteria were applied to exclude patients with disorders that might elevate inflammatory markers.</li> <li>It is unclear whether the reference standard was performed the same way for all study participants.</li> </ul>
Johnson, 2011 <sup>21</sup>	Unclear	L	L	L	L	L	L	<ul style="list-style-type: none"> <li>Not all of potentially eligible cases were included in the study.</li> </ul>
Paakkonen, 2010 <sup>22</sup>	H	L	L	Unclear	Unclear	L	L	<ul style="list-style-type: none"> <li>Study population consisted of culture (reference standard)-positive cases, i.e., culture-negative cases were excluded from ESR/CRP testing and, hence, from the analysis.</li> <li>The study excluded immune-deficient patients.</li> <li>The final diagnosis of various infection types was made using different clinical tests.</li> <li>The schedules of measuring ESR and CRP differed.</li> </ul>
Ghanem, 2009 <sup>25</sup>	Unclear	L	L	L	L	L	L	<ul style="list-style-type: none"> <li>Retrospective chart review.</li> <li>Broad exclusion criteria were applied to exclude patients with disorders that might elevate inflammatory markers.</li> </ul>
Austin, 2008 <sup>23</sup>	Unclear	L	L	L	L	L	L	<ul style="list-style-type: none"> <li>Not all of potentially eligible cases were included in the study, i.e., only patients who had both ESR and CRP measurements were included.</li> <li>Broad exclusion criteria were applied to exclude patients with disorders that might elevate inflammatory markers.</li> </ul>
Dolwani, 2004 <sup>24</sup>	H	L	L	Unclear	L	L	L	<ul style="list-style-type: none"> <li>The study used a case-control design to estimate the diagnostic performance of the study tests.</li> <li>Patients who were diagnosed as positive by</li> </ul>

Study Author, Year	Risk of Bias			Applicability Concerns			Potential Issues
	Patient Selection	Index Test	Reference Standard	Follow & Timing	Patient Selection	Index Test	
							<p>rigid sigmoidoscopy or stool culture tests were excluded from the “case” group, with no explanation as to why.</p> <ul style="list-style-type: none"> <li>• Unclear description of scheduling of study tests in each study group.</li> <li>• In addition to a control group of patients with Crohn’s disease, the study included a control group of healthy volunteers for whom ESR and CRP tests were not performed.</li> </ul>
Hayreh, 1997 <sup>28</sup>	H	L	L	H	L	L	<ul style="list-style-type: none"> <li>• The study used a case-control design to estimate the diagnostic performance of the study tests.</li> <li>• Patients with disorders that might elevate inflammatory markers were excluded.</li> <li>• Unclear description of scheduling of study tests in each study group.</li> <li>• Only a subset of patients, who received both ESR and CRP tests, were included in the analysis of combined ESR and CRP test results.</li> </ul>

CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; GCA = giant cell arteritis; H = high; L = low.

## Appendix 11: Test Characteristics and Estimated Test Results Using Data From Included Studies

Study	Test	Cut-Off Point	Reference Standard	Total Sample Size	Disease Frequency (%) <sup>a</sup>	TP	FP	TN	FN
<b>Diagnosis of Periprosthetic Infection</b>									
Costa, 2012 <sup>18</sup>	ESR	> 30 mm/h	Synovial fluid bacterial culture	77	89.61	61	3	5	8
	CRP	> 10 mg/L				64	5	3	5
	ESR + CRP	Same as above				58	2	6	11
	ESR/CRP	Same as above				65	8	2	2
Johnson, 2011 <sup>21</sup>	ESR	> 30 mm/h	At least one of the following: (1) ≥ 2 positive cultures with the same organism, (2) positive histological findings for acute inflammatory response on intraoperative frozen section, (3) macroscopic purulence, or (4) a draining sinus tract communicates with the joint space.	113	84.07	86	12	6	9
	CRP	> 10 mg/L				90	14	4	5
	ESR + CRP	Same as above				85	13	5	10
	ESR/CRP	Same as above				90	11	7	5
Ghanem, 2009 <sup>25</sup>	ESR	> 30 mm/h	At least one of the following: (1) an abscess or sinus tract that communicates with the joint space, (2) positive preoperative aspiration culture, (3) ≥ 2 positive intraoperative cultures or one positive culture and the presence of other indicators of infection includes macroscopic purulence or an elevated cell count and differential of the aspirate fluid.	479	26.50	120	105	247	7
	CRP	> 10 mg/L				116	82	270	11
	ESR + CRP	Same as above				111	42	310	16
	ESR/CRP	Same as above				124	145	207	3
Austin, 2008 <sup>23</sup>	ESR	> 30 mm/h	Synovial fluid culture	296	39.19	106	50	130	10
	CRP	> 10 mg/L				109	47	133	7
	ESR + CRP	Not applicable				NA	NA	NA	NA
	ESR/CRP	Same as above				111	79	101	5
<b>Diagnosis of Pediatric Orthopedic Infections</b>									
Robinson, 2012 <sup>20</sup>	ESR	> 12 mm/h	Diagnosis of infection by an orthopedic consultant and history of antibiotic therapy	259	6.56	15	83	159	2
	CRP	> 7 mg/L				12	32	210	5
	ESR + CRP	Same as above				11	25	217	6
	ESR/CRP	Same as above				NA	NA	NA	NA

Study	Test	Cut-Off Point	Reference Standard	Total Sample Size	Disease Frequency (%) <sup>a</sup>	TP	FP	TN	FN
Paakkonen, 2010 <sup>22</sup>	ESR	> 20 mm/h	Blood culture, bone/joint needle aspiration and culture	NA <sup>b</sup>	NA <sup>b</sup>	248	NA	NA	17
	CRP	> 20 mg/L				251	NA	NA	14
	ESR + CRP	Not applicable				NA	NA	NA	NA
	ESR/CRP	Same as above				261	NA	NA	4
<b>Diagnosis of Pediatric Bronchiolitis</b>									
Grzesk, 2012 <sup>27</sup>	ESR	> 15 mm/h	Clinical symptoms, chest X-ray, white blood cell count, and bacteriological tests (for suspected lower respiratory tract infections)	149	11 (bacterial infection)	NA	NA	NA	NA
	CRP	> 15 mg/L				NA	NA	NA	NA
	ESR + CRP	Same as above				NA	NA	NA	NA
	ESR/CRP	Not applicable				NA	NA	NA	NA
<b>Diagnosis of Inflammatory Bowel Diseases</b>									
Dolwani, 2004 <sup>24</sup>	ESR	≥ 10 mm/h	Barium Follow-Through (BaFT)	63	23.81	12	16	32	3
	CRP	≥ 6 mg/L				12	14	34	3
	ESR + CRP	Same as above				8	8	40	7
	ESR/CRP	Not applicable				NA	NA	NA	NA
<b>Diagnosis of Giant Cell Arteritis</b>									
Kermani, 2012 <sup>19</sup>	ESR	> 22 mm/h (men); > 29 mm/h (women)	Temporal artery biopsy	764	23.17	149	414	173	28
	CRP	> 8 mg/L				153	408	179	24
	ESR + CRP	Same as above				143	345	242	34
	ESR/CRP	Not applicable				NA	NA	NA	NA
Hayreh, 1997 <sup>28</sup>	ESR	> 10 mm/h (men); > 20 mm/h (women)	Temporal artery biopsy	855 (ESR sample) <sup>c</sup> 181 (CRP and ESR sub-sample) <sup>d</sup>	29.20 (total, ESR, sample) 19.28 (CRP and ESR sub-sample)	103	247	502	3
	CRP	> 5 mg/L				43	25	113	0
	ESR + CRP	Same as above				42	11	127	1
	ESR/CRP	Not applicable				NA	NA	NA	NA

CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; FN = false-negative; FP = false-positive; NA = not available; TN = true-negative; TP = true-positive

<sup>a</sup> Proportion of patients who received confirmation of the diagnosis (disease-positive) by the reference standard.

<sup>b</sup> This study analyzed only the cases diagnosed as "disease-positive" by the reference standard.

<sup>c</sup> Diagnostic accuracy measures were calculated using the data from patients with positive temporal artery biopsy (n = 106 out of 363) and the control group (n = 749).

<sup>d</sup> Diagnostic accuracy measures were calculated using the data from patients with positive temporal artery biopsy (n = 43 out of 223) and the corresponding control group (n = 138).

## Appendix 12: Diagnostic Performance of ESR and CRP Individually and in Combination Compared With the Reference Standard

Study	Test	Sensitivity <sup>a</sup> (95% CI)	Specificity <sup>a</sup> (95% CI)	PPV <sup>a</sup> (95% CI)	NPV <sup>a</sup> (95% CI)	LR (+) <sup>a</sup> (95% CI)	LR (-) <sup>a</sup> (95% CI)	AUC <sup>a</sup> (95% CI)	ODA <sup>a</sup> (95% CI)
<b>Diagnosis of Periprosthetic Infection</b>									
Costa, 2012 <sup>18</sup>	ESR	<b>0.89<sup>b</sup></b> (0.81 to 0.99)	0.63 <sup>b</sup> (0.29 to 0.96)	0.95 (0.90 to 1.00)	0.38 (0.12 to 0.65)	2.36 (1.01 to 5.48)	0.19 (0.08 to 0.46)	0.755 <sup>b</sup> (0.273 to 1.236)	0.86 (0.78 to 0.94)
	CRP	<b>0.93<sup>b</sup></b> (0.87 to 0.99)	0.38 <sup>b</sup> (0.40 to 0.71)	0.93 (0.87 to 0.99)	0.38 (0.04 to 0.71)	1.48 (0.43 to 5.08)	0.19 (0.11 to 0.33)	0.651 <sup>b</sup> (0.241 to 1.062)	0.87 (0.80 to 0.95)
	ESR + CRP	<b>0.84<sup>b</sup></b> (0.75 to 0.98)	0.75 <sup>b</sup> (0.45 to 1.00)	0.97 (0.92 to 1.01)	0.35 (0.13 to 0.58)	3.36 (1.71 to 6.59)	0.21 (0.06 to 0.71)	0.795 (0.303 to 1.288)	0.83 (0.75 to 0.91)
	ESR/CRP	<b>0.97<sup>b</sup></b> <b>(0.93 to 1.00)</b>	0.20 <sup>b</sup> (0.00 to 0.45)	0.89 (0.82 to 0.96)	0.50 (0.01 to 0.99)	1.21 (0.19 to 7.67)	0.15 (0.11 to 0.20)	0.585 (0.280 to 0.890)	0.87 (0.80 to 0.95)
Johnson, 2011 <sup>21</sup>	ESR	<b>0.91</b> <b>(0.83 to 0.95)</b>	<b>0.33</b> <b>(0.12 to 0.65)</b>	0.88 (0.81 to 0.94)	0.40 (0.15 to 0.65)	1.36 (0.55 to 3.35)	0.28 (0.20 to 0.40)	0.619 (0.355 to 0.884)	0.81 (0.74 to 0.89)
	CRP	<b>0.95</b> <b>(0.88 to 0.98)</b>	<b>0.20</b> <b>(0.06 to 0.50)</b>	0.87 (0.80 to 0.93)	0.44 (0.12 to 0.77)	1.22 (0.36 to 4.10)	0.24 (0.18 to 0.30)	0.585 (0.347 to 0.822)	0.83 (0.76 to 0.90)
	ESR + CRP	<b>0.89</b> <b>(0.87 to 0.97)</b>	<b>0.29</b> <b>(0.10 to 0.59)</b>	0.87 (0.80 to 0.93)	0.33 (0.09 to 0.57)	1.24 (0.48 to 3.20)	0.38 (0.28 to 0.51)	0.586 (0.341 to 0.831)	0.80 (0.72 to 0.87)
	ESR/CRP	<b>0.95</b> <b>(0.89 to 0.98)</b>	<b>0.38</b> <b>(0.14 to 0.69)</b>	0.89 (0.83 to 0.95)	0.58 (0.30 to 0.86)	1.55 (0.55 to 4.35)	0.14 (0.09 to 0.20)	0.668 (0.377 to 0.959)	0.86 (0.79 to 0.92)
Ghanem, 2009 <sup>25</sup>	ESR	<b>0.94</b> <b>(0.89 to 0.98)</b>	<b>0.70</b> <b>(0.65 to 0.75)</b>	<b>0.56</b> <b>(0.48 to 0.62)</b>	<b>0.97</b> <b>(0.94 to 0.99)</b>	<b>3.10</b> <b>(0.70 to 7.90)</b>	<b>0.09</b> <b>(0.03 to 0.27)</b>	0.823 (0.776 to 0.871)	0.77 (0.73 to 0.80)
	CRP	<b>0.91</b> <b>(0.85 to 0.95)</b>	<b>0.77</b> <b>(0.72 to 0.81)</b>	<b>0.61</b> <b>(0.53 to 0.68)</b>	<b>0.96</b> <b>(0.92 to 0.98)</b>	<b>4.10</b> <b>(2.30 to 7.20)</b>	<b>0.13</b> <b>(0.05 to 0.38)</b>	0.840 (0.781 to 0.899)	0.81 (0.77 to 0.84)

Study	Test	Sensitivity <sup>a</sup> (95% CI)	Specificity <sup>a</sup> (95% CI)	PPV <sup>a</sup> (95% CI)	NPV <sup>a</sup> (95% CI)	LR (+) <sup>a</sup> (95% CI)	LR (-) <sup>a</sup> (95% CI)	AUC <sup>a</sup> (95% CI)	ODA <sup>a</sup> (95% CI)
	ESR + CRP	<b>0.88</b> (0.81 to 0.93)	<b>0.88</b> (0.84 to 0.92)	<b>0.75</b> (0.66 to 0.81)	<b>0.95</b> (0.92 to 0.97)	<b>7.50</b> (2.40 to 18.30)	<b>0.20</b> (0.09 to 0.38)	0.877 (0.800 to 0.954)	0.88 (0.85 to 0.91)
	ESR/CRP	<b>0.98</b> (0.93 to 0.99)	<b>0.59</b> (0.53 to 0.64)	<b>0.48</b> (0.42 to 0.54)	<b>0.98</b> (0.95 to 0.99)	<b>2.50</b> (1.50 to 4.40)	<b>0.04</b> (0.01 to 0.16)	0.782 (0.759 to 0.806)	0.69 (0.65 to 0.73)
Austin, 2008 <sup>23</sup>	ESR	<b>0.91</b> (0.86 to 0.97)	<b>0.72</b> (0.66 to 0.79)	<b>0.68</b> (0.61 to 0.75)	<b>0.93</b> (0.89 to 0.97)	3.29 (1.81 to 5.99)	0.12 (0.09 to 0.15)	0.818 (0.722 to 0.914)	0.80 (0.75 to 0.84)
	CRP	<b>0.94</b> (0.90 to 0.98)	<b>0.74</b> (0.68 to 0.80)	<b>0.70</b> (0.63 to 0.77)	<b>0.95</b> (0.91 to 0.99)	3.60 (1.75 to 7.42)	0.08 (0.06 to 0.10)	0.839 (0.739 to 0.939)	0.82 (0.77 to 0.8)
	ESR + CRP	NA	NA	NA	NA	NA	NA	NA	NA
	ESR/CRP	<b>0.96</b> (0.92 to 0.99)	<b>0.56</b> (0.49 to 0.63)	<b>0.58</b> (0.51 to 0.65)	<b>0.95</b> (0.91 to 0.99)	2.18 (0.92 to 5.19)	0.08 (0.06 to 0.09)	0.759 (0.681 to 0.837)	0.72 (0.66 to 0.77)
<b>Diagnosis of Pediatric Orthopedic Infections</b>									
Robinson, 2012 <sup>20</sup>	ESR	<b>0.88</b> (0.73 to 1.04)	<b>0.66</b> (0.60 to 0.72)	0.15 (0.08 to 0.22)	0.99 (0.97 to 1.00)	<b>2.57</b> (0.70 to 0.949)	0.18 (0.14 to 0.23)	0.770 (0.591 to 0.948)	0.67 (0.61 to 0.73)
	CRP	<b>0.71</b> (0.45 to 0.92)	<b>0.87</b> (0.83 to 0.91)	0.27 (0.14 to 0.40)	0.98 (0.96 to 1.00)	<b>5.34</b> (2.55 to 11.17)	0.34 (0.22 to 0.53)	0.787 (0.743 to 0.831)	0.86 (0.81 to 0.90)
	ESR + CRP	0.65 ( <b>0.42 to 0.87</b> )	0.90 (0.86 to 0.94)	0.31 (0.16 to 0.46)	0.97 (0.95 to 0.99)	<b>6.26</b> (3.29 to 11.94)	0.39 (0.24 to 0.66)	0.772 (0.708 to 0.835)	0.88 (0.84 to 0.92)
	ESR/CRP	NA	NA	NA	NA	NA	NA	NA	NA
Paakkonen, 2010 <sup>22</sup>	ESR	<b>0.94</b> (0.90 to 0.96)	NA	NA	NA	NA	NA	NA	NA
	CRP	<b>0.95</b> (0.91 to 0.97)	NA	NA	NA	NA	NA	NA	NA
	ESR + CRP	NA	NA	NA	NA	NA	NA	NA	NA
	ESR/CRP	<b>0.98</b>	NA	NA	NA	NA	NA	NA	NA

Study	Test	Sensitivity <sup>a</sup> (95% CI)	Specificity <sup>a</sup> (95% CI)	PPV <sup>a</sup> (95% CI)	NPV <sup>a</sup> (95% CI)	LR (+) <sup>a</sup> (95% CI)	LR (-) <sup>a</sup> (95% CI)	AUC <sup>a</sup> (95% CI)	ODA <sup>a</sup> (95% CI)
		<b>(0.96 to 0.99)</b>							
<b>Diagnosis of Pediatric Bronchiolitis</b>									
Grzesk, 2012 <sup>2726</sup>	ESR	NA	NA	NA	NA	NA	NA	0.710 (0.600 to 0.830)	NA
	CRP	NA	NA	NA	NA	NA	NA	0.630 (0.510 to 0.750)	NA
	ESR+CRP	NA	NA	NA	NA	NA	NA	0.74 (0.600 to 0.880)	NA
	ESR/CRP	NA	NA	NA	NA	NA	NA	NA	NA
<b>Diagnosis of Inflammatory Bowel Diseases</b>									
Dolwani, 2004 <sup>24</sup>	ESR	<b>0.79</b> (0.60 to 1.00)	<b>0.67</b> (0.53 to 0.80)	<b>0.42</b> (0.25 to 0.61)	<b>0.91</b> (0.82 to 1.01)	2.40 (0.86 to 6.73)	0.30 (0.19 to 0.48)	0.733 (0.662 to 0.805)	0.70 (0.59 to 0.81)
	CRP	<b>0.77</b> (0.60 to 1.00)	<b>0.70</b> <b>(0.58 to 0.84)</b>	0.46 <sup>c</sup> (0.27 to 0.65)	<b>0.91</b> (0.83 to 1.01)	2.74 (0.98 to 7.67)	0.28 (0.17 to 0.47)	0.754 (0.659 to 0.850)	0.73 (0.62 to 0.84)
	ESR + CRP	<b>0.50</b> (0.28 to 0.79)	<b>0.84</b> (0.73 to 0.94)	<b>0.5</b> (0.26 to 0.75)	<b>0.84</b> (0.75 to 0.95)	3.20 (1.84 to 5.58)	0.56 (0.25 to 1.23)	0.683 (0.531 to 0.836)	0.76 (0.66 to 0.87)
	ESR/CRP	NA	NA	NA	NA	NA	NA	NA	NA
<b>Diagnosis of Giant Cell Arteritis</b>									
Kermani, 2012 <sup>19</sup>	ESR	<b>0.84</b> (0.79 to 0.90)	<b>0.30</b> (0.26 to 0.33)	<b>0.26</b> (0.23 to 0.30)	0.86 (0.81 to 0.91)	1.19 (0.83 to 1.71)	0.54 (0.49 to 0.58)	0.568 (0.551 to 0.586)	0.42 (0.39 to 0.46)
	CRP	<b>0.86</b> (0.81 to 0.92)	<b>0.31</b> (0.27 to 0.34)	<b>0.27</b> (0.24 to 0.31)	0.88 (0.84 to 0.93)	1.24 (0.84 to 1.84)	0.44 (0.41 to 0.48)	0.585 (0.564 to 0.606)	0.43 (0.40 to 0.47)
	ESR + CRP	<b>0.81</b> (0.75 to 0.87)	<b>0.41</b> (0.37 to 0.45)	<b>0.29</b> (0.25 to 0.33)	0.88 (0.84 to 0.92)	1.37 (1.00 to 1.89)	0.47 (0.42 to 0.51)	0.610 (0.588 to 0.632)	0.50 (0.47 to 0.54)
	ESR/CRP	NA	NA	NA	NA	NA	NA	NA	NA

Study	Test	Sensitivity <sup>a</sup> (95% CI)	Specificity <sup>a</sup> (95% CI)	PPV <sup>a</sup> (95% CI)	NPV <sup>a</sup> (95% CI)	LR (+) <sup>a</sup> (95% CI)	LR (-) <sup>a</sup> (95% CI)	AUC <sup>a</sup> (95% CI)	ODA <sup>a</sup> (95% CI)
Hayreh, 1997 <sup>28</sup>	ESR	0.97 (0.92 to 0.99)	0.67 (0.64 to 0.72)	0.29 (0.25 to 0.34)	0.99 (0.98 to 1.00)	2.95 (0.96 to 9.00)	0.04 (0.04 to 0.05)	0.821 (0.821 to 0.821)	0.71 (0.68 to 0.74)
	CRP	1.00 (0.93 to 1.00)	0.82 (0.74 to 0.88)	0.63 (0.51 to 0.75)	1.00 (0.97 to 1.00)	5.52 (NA)	0.00 (NA)	0.909 (0.909 to 0.909)	0.86 (0.81 to 0.91)
	ESR + CRP	0.98 (0.88 to 1.00)	0.92 (0.86 to 0.96)	0.93 (0.81 to 0.94)	0.99 (0.96 to 1.00)	12.25 (1.76 to 85.07)	0.03 (0.01 to 0.04)	0.949 (0.949 to 0.949)	0.93 (0.90 to 0.97)
	ESR/CRP	NA	NA	NA	NA	NA	NA	NA	NA

AUC = area under the curve; CRP = C-reactive protein; CI = confidence interval; ESR = erythrocyte sedimentation rate; LR (+) = positive likelihood ratio; LR (-) = negative likelihood ratio; NPV = negative predictive value; NA = not available; ODA = overall diagnostic accuracy; PPV = positive predictive value.

<sup>a</sup> The estimates are calculated using available parameters from the included studies.

<sup>b</sup> The reported sensitivity and specificity values and their 95% CIs (calculated using Wilson score method) were reported as follows: ESR sensitivity 0.89 (0.80 to 0.94) and specificity 0.69 (0.51 to 0.83); CRP sensitivity 0.93 (0.85 to 0.97) and specificity 0.40 (0.23 to 0.59); ESR + CRP sensitivity 0.84 (0.73 to 0.91) and specificity 0.77 (0.57 to 0.90), and ESR/CRP sensitivity 0.97 (0.90 to 0.99) and specificity 0.23 (0.10 to 0.43).

<sup>c</sup> The specificity value for CRP, reported by the authors, was 0.42.

Note: The estimates reported by the authors of the articles are presented in bold font, and the calculated measures are presented in regular font. When the reported values were different from reviewers' calculated values, only calculated values are shown in the table, for consistency and reproducibility of the data.